WO2013030288A1 - Substituierte annellierte pyrimidine und ihre verwendung - Google Patents
Substituierte annellierte pyrimidine und ihre verwendung Download PDFInfo
- Publication number
- WO2013030288A1 WO2013030288A1 PCT/EP2012/066876 EP2012066876W WO2013030288A1 WO 2013030288 A1 WO2013030288 A1 WO 2013030288A1 EP 2012066876 W EP2012066876 W EP 2012066876W WO 2013030288 A1 WO2013030288 A1 WO 2013030288A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluorine
- group
- alkyl
- trifluoromethyl
- methyl
- Prior art date
Links
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 title claims description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 29
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- 238000011321 prophylaxis Methods 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 340
- 239000011737 fluorine Substances 0.000 claims description 340
- -1 hydroxy, hydroxycarbonyl Chemical group 0.000 claims description 338
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 298
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 280
- 125000001424 substituent group Chemical group 0.000 claims description 278
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 263
- 229910052739 hydrogen Inorganic materials 0.000 claims description 216
- 239000001257 hydrogen Substances 0.000 claims description 216
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 178
- 125000000623 heterocyclic group Chemical group 0.000 claims description 166
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 159
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 155
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 151
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 144
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 142
- 125000002393 azetidinyl group Chemical group 0.000 claims description 139
- 150000003839 salts Chemical class 0.000 claims description 138
- 150000001875 compounds Chemical class 0.000 claims description 129
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 127
- 239000012453 solvate Substances 0.000 claims description 127
- 125000003386 piperidinyl group Chemical group 0.000 claims description 124
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 124
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 120
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 118
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 116
- 125000002757 morpholinyl group Chemical group 0.000 claims description 116
- 125000004193 piperazinyl group Chemical group 0.000 claims description 114
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 104
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 102
- 125000004076 pyridyl group Chemical group 0.000 claims description 96
- 125000004043 oxo group Chemical group O=* 0.000 claims description 93
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 93
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 86
- 125000001425 triazolyl group Chemical group 0.000 claims description 81
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 77
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 76
- 125000001153 fluoro group Chemical group F* 0.000 claims description 72
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims description 71
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 64
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 claims description 59
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 58
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 57
- 125000000335 thiazolyl group Chemical group 0.000 claims description 57
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 56
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 56
- 125000000217 alkyl group Chemical group 0.000 claims description 53
- 125000002971 oxazolyl group Chemical group 0.000 claims description 51
- 125000002883 imidazolyl group Chemical group 0.000 claims description 50
- 125000003566 oxetanyl group Chemical group 0.000 claims description 48
- 125000004429 atom Chemical group 0.000 claims description 45
- 239000000460 chlorine Substances 0.000 claims description 43
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 41
- 229910052801 chlorine Inorganic materials 0.000 claims description 41
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 38
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 37
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 36
- 229910052757 nitrogen Inorganic materials 0.000 claims description 36
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 36
- PIGFYZPCRLYGLF-UHFFFAOYSA-N Aluminum nitride Chemical compound [Al]#N PIGFYZPCRLYGLF-UHFFFAOYSA-N 0.000 claims description 35
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 34
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 31
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 30
- 229910052799 carbon Inorganic materials 0.000 claims description 28
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 28
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 28
- 125000002541 furyl group Chemical group 0.000 claims description 26
- 150000001204 N-oxides Chemical class 0.000 claims description 23
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 21
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 19
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 19
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 18
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 18
- 125000003545 alkoxy group Chemical group 0.000 claims description 17
- 125000004432 carbon atom Chemical group C* 0.000 claims description 17
- 239000002904 solvent Substances 0.000 claims description 15
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 14
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 14
- 125000001072 heteroaryl group Chemical group 0.000 claims description 14
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 12
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 229920006395 saturated elastomer Polymers 0.000 claims description 12
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 11
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 11
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 11
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 10
- 239000012442 inert solvent Substances 0.000 claims description 10
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 8
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 7
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 206010002383 Angina Pectoris Diseases 0.000 claims description 6
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 206010020772 Hypertension Diseases 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 230000003176 fibrotic effect Effects 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 5
- 208000019553 vascular disease Diseases 0.000 claims description 5
- 150000007513 acids Chemical class 0.000 claims description 4
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 claims description 4
- 230000009424 thromboembolic effect Effects 0.000 claims description 4
- 125000006555 (C3-C5) cycloalkyl group Chemical group 0.000 claims description 3
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims description 3
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229940082615 organic nitrates used in cardiac disease Drugs 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims 4
- 201000006370 kidney failure Diseases 0.000 claims 4
- 208000002815 pulmonary hypertension Diseases 0.000 claims 4
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 5
- 150000003230 pyrimidines Chemical class 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 238000002955 isolation Methods 0.000 abstract description 2
- 150000002431 hydrogen Chemical class 0.000 description 102
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 26
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 24
- 150000001721 carbon Chemical group 0.000 description 22
- 238000006243 chemical reaction Methods 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 14
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 14
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 13
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 description 12
- 102000007637 Soluble Guanylyl Cyclase Human genes 0.000 description 11
- 108010007205 Soluble Guanylyl Cyclase Proteins 0.000 description 11
- 239000011734 sodium Substances 0.000 description 11
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 201000003883 Cystic fibrosis Diseases 0.000 description 7
- 108010078321 Guanylate Cyclase Proteins 0.000 description 7
- 102000014469 Guanylate cyclase Human genes 0.000 description 7
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 7
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 7
- 229910000024 caesium carbonate Inorganic materials 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000011591 potassium Substances 0.000 description 7
- 125000004847 2-fluorobenzyl group Chemical group [H]C1=C([H])C(F)=C(C([H])=C1[H])C([H])([H])* 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 238000006751 Mitsunobu reaction Methods 0.000 description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical class OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229910052783 alkali metal Inorganic materials 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 150000003278 haem Chemical class 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- 229910052808 lithium carbonate Inorganic materials 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Inorganic materials [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 229910000027 potassium carbonate Inorganic materials 0.000 description 4
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 4
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000008096 xylene Substances 0.000 description 4
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 208000009729 Ventricular Premature Complexes Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000009977 dual effect Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 2
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 2
- 125000006763 (C3-C9) cycloalkyl group Chemical group 0.000 description 2
- VLSDXINSOMDCBK-BQYQJAHWSA-N (E)-1,1'-azobis(N,N-dimethylformamide) Chemical compound CN(C)C(=O)\N=N\C(=O)N(C)C VLSDXINSOMDCBK-BQYQJAHWSA-N 0.000 description 2
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 2
- RQFCJASXJCIDSX-UHFFFAOYSA-N 14C-Guanosin-5'-monophosphat Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(O)=O)C(O)C1O RQFCJASXJCIDSX-UHFFFAOYSA-N 0.000 description 2
- NNSYGSLTPSOCOZ-UHFFFAOYSA-N 2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-4-[(3,3,3-trifluoro-2-hydroxypropyl)amino]-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(NCC(O)C(F)(F)F)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F NNSYGSLTPSOCOZ-UHFFFAOYSA-N 0.000 description 2
- GNETVOUSGGAEDK-UHFFFAOYSA-N 4-bis[4-(dimethylamino)phenyl]phosphanyl-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1P(C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 GNETVOUSGGAEDK-UHFFFAOYSA-N 0.000 description 2
- QGHFTIKMLOOOSM-UHFFFAOYSA-N 5-fluoro-1-[(2-fluorophenyl)methyl]-3-iodopyrazolo[3,4-b]pyridine Chemical compound N1=C(I)C2=CC(F)=CN=C2N1CC1=CC=CC=C1F QGHFTIKMLOOOSM-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ATOAHNRJAXSBOR-UHFFFAOYSA-N BAY 41-2272 Chemical compound NC1=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=C1C1CC1 ATOAHNRJAXSBOR-UHFFFAOYSA-N 0.000 description 2
- 229940127280 BAY 41-2272 Drugs 0.000 description 2
- 206010007556 Cardiac failure acute Diseases 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 206010048554 Endothelial dysfunction Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical class Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- BERDEBHAJNAUOM-UHFFFAOYSA-N copper(i) oxide Chemical compound [Cu]O[Cu] BERDEBHAJNAUOM-UHFFFAOYSA-N 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 2
- NZZFYRREKKOMAT-UHFFFAOYSA-N diiodomethane Chemical compound ICI NZZFYRREKKOMAT-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- GUVUOGQBMYCBQP-UHFFFAOYSA-N dmpu Chemical compound CN1CCCN(C)C1=O GUVUOGQBMYCBQP-UHFFFAOYSA-N 0.000 description 2
- 230000008694 endothelial dysfunction Effects 0.000 description 2
- 239000000066 endothelium dependent relaxing factor Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 2
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Chemical class OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 150000005229 pyrazolopyridines Chemical class 0.000 description 2
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 235000010288 sodium nitrite Nutrition 0.000 description 2
- 229940127296 soluble guanylate cyclase stimulator Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Chemical class OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical class OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- QFMZQPDHXULLKC-UHFFFAOYSA-N 1,2-bis(diphenylphosphino)ethane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 QFMZQPDHXULLKC-UHFFFAOYSA-N 0.000 description 1
- FFWQLZFIMNTUCZ-UHFFFAOYSA-N 1-(bromomethyl)-2-fluorobenzene Chemical compound FC1=CC=CC=C1CBr FFWQLZFIMNTUCZ-UHFFFAOYSA-N 0.000 description 1
- 125000006218 1-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- KUMKNGTWQNSAQW-UHFFFAOYSA-N 2-(2-fluorophenyl)acetyl chloride Chemical compound FC1=CC=CC=C1CC(Cl)=O KUMKNGTWQNSAQW-UHFFFAOYSA-N 0.000 description 1
- ORIHZIZPTZTNCU-UHFFFAOYSA-N 2-(hydroxyiminomethyl)phenol Chemical compound ON=CC1=CC=CC=C1O ORIHZIZPTZTNCU-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical class CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- LMMQIUYHRPPZCJ-UHFFFAOYSA-N 2-[1-[(2,3-difluorophenyl)methyl]-5-fluoropyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-1,7-dihydropyrrolo[2,3-d]pyrimidine-4,6-dione Chemical compound N=1C(O)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC(F)=C1F LMMQIUYHRPPZCJ-UHFFFAOYSA-N 0.000 description 1
- USYOSKSEOJLODR-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-(2-hydroxyethoxy)-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(OCCO)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F USYOSKSEOJLODR-UHFFFAOYSA-N 0.000 description 1
- XUCPREUJJMPCAO-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-(2-hydroxypropylamino)-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C=2NC(=O)C(C)(C)C=2C(NCC(O)C)=NC=1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F XUCPREUJJMPCAO-UHFFFAOYSA-N 0.000 description 1
- BZAINAFHTOHDIS-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-(4-hydroxypyrazol-1-yl)-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)(C)C(=O)NC2=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=1N1C=C(O)C=N1 BZAINAFHTOHDIS-UHFFFAOYSA-N 0.000 description 1
- GSXCCMBFEBSIEX-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-methoxy-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C=2NC(=O)C(C)(C)C=2C(OC)=NC=1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F GSXCCMBFEBSIEX-UHFFFAOYSA-N 0.000 description 1
- FQWHDNCKUIACMP-UHFFFAOYSA-N 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-1,7-dihydropyrrolo[2,3-d]pyrimidine-4,6-dione Chemical compound N=1C(O)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F FQWHDNCKUIACMP-UHFFFAOYSA-N 0.000 description 1
- AEDOVXYXUVJVOG-UHFFFAOYSA-N 2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-(2-hydroxyethylamino)-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(NCCO)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F AEDOVXYXUVJVOG-UHFFFAOYSA-N 0.000 description 1
- IYOYKMJWQRIASR-UHFFFAOYSA-N 2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-[(1-hydroxycyclopropyl)methylamino]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)(C)C(=O)NC2=NC(C=2C3=CC(F)=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=1NCC1(O)CC1 IYOYKMJWQRIASR-UHFFFAOYSA-N 0.000 description 1
- WBMAUHBOMFDWDS-UHFFFAOYSA-N 2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-4-[(2-hydroxy-2-methylpropyl)amino]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C=2NC(=O)C(C)(C)C=2C(NCC(C)(O)C)=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F WBMAUHBOMFDWDS-UHFFFAOYSA-N 0.000 description 1
- NTZXIUCASKGROB-UHFFFAOYSA-N 2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-1,7-dihydropyrrolo[2,3-d]pyrimidine-4,6-dione Chemical compound N=1C(O)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F NTZXIUCASKGROB-UHFFFAOYSA-N 0.000 description 1
- CITHDBFODIJUDU-UHFFFAOYSA-N 2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-4-(2,2,2-trifluoroethylamino)-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(NCC(F)(F)F)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F CITHDBFODIJUDU-UHFFFAOYSA-N 0.000 description 1
- JDKFGGYPXSUPEH-UHFFFAOYSA-N 2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-4-(3,3,3-trifluoropropylamino)-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(NCCC(F)(F)F)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F JDKFGGYPXSUPEH-UHFFFAOYSA-N 0.000 description 1
- YNZKKGMWWPIXLA-UHFFFAOYSA-N 2-[5-fluoro-3-[(2-fluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-1,7-dihydropyrrolo[2,3-d]pyrimidine-4,6-dione Chemical compound N=1C(O)=C2C(C)(C)C(=O)NC2=NC=1N(C1=CC=C(F)C=C11)N=C1CC1=CC=CC=C1F YNZKKGMWWPIXLA-UHFFFAOYSA-N 0.000 description 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000005916 2-methylpentyl group Chemical group 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- NPAXPTHCUCUHPT-UHFFFAOYSA-N 3,4,7,8-tetramethyl-1,10-phenanthroline Chemical compound CC1=CN=C2C3=NC=C(C)C(C)=C3C=CC2=C1C NPAXPTHCUCUHPT-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical class NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000005917 3-methylpentyl group Chemical group 0.000 description 1
- PWNLEGTUORZMTM-UHFFFAOYSA-N 3-pyrimidin-2-yl-1h-pyrazolo[4,3-b]pyridine Chemical class N1=CC=CN=C1C1=NNC2=CC=CN=C12 PWNLEGTUORZMTM-UHFFFAOYSA-N 0.000 description 1
- AWJGHJKFOXVYPK-UHFFFAOYSA-N 4-(2,2-difluoroethylamino)-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound N=1C(NCC(F)F)=C2C(C)(C)C(=O)NC2=NC=1C(C1=CC(F)=CN=C11)=NN1CC1=CC=CC=C1F AWJGHJKFOXVYPK-UHFFFAOYSA-N 0.000 description 1
- IZUMKIOMVLEBQX-UHFFFAOYSA-N 4-(3-aminopyrrolidin-1-yl)-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)(C)C(=O)NC2=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=1N1CCC(N)C1 IZUMKIOMVLEBQX-UHFFFAOYSA-N 0.000 description 1
- AQHAOLJURMOWBH-UHFFFAOYSA-N 4-(3-ethyl-2-oxoimidazolidin-1-yl)-2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound O=C1N(CC)CCN1C1=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC2=C1C(C)(C)C(=O)N2 AQHAOLJURMOWBH-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical class COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- NNLSZXYWRIJCTF-UHFFFAOYSA-N 4-(cyclopropylmethylamino)-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)(C)C(=O)NC2=NC(C=2C3=CC(F)=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=1NCC1CC1 NNLSZXYWRIJCTF-UHFFFAOYSA-N 0.000 description 1
- CSLCMWJZLUFUSU-UHFFFAOYSA-N 4-(cyclopropylmethylamino)-2-[5-fluoro-3-[(2-fluorophenyl)methyl]indazol-1-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)(C)C(=O)NC2=NC(N2C3=CC=C(F)C=C3C(CC=3C(=CC=CC=3)F)=N2)=NC=1NCC1CC1 CSLCMWJZLUFUSU-UHFFFAOYSA-N 0.000 description 1
- QMBQDWWPHWEBIE-UHFFFAOYSA-N 4-[(2,2-difluorocyclopropyl)methylamino]-2-[5-fluoro-1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5,5-dimethyl-7h-pyrrolo[2,3-d]pyrimidin-6-one Chemical compound C=12C(C)(C)C(=O)NC2=NC(C=2C3=CC(F)=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=1NCC1CC1(F)F QMBQDWWPHWEBIE-UHFFFAOYSA-N 0.000 description 1
- 150000005007 4-aminopyrimidines Chemical class 0.000 description 1
- GOEGBJDTWXTPHP-UHFFFAOYSA-N 4-diphenylphosphanyl-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 GOEGBJDTWXTPHP-UHFFFAOYSA-N 0.000 description 1
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical group NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 208000003017 Aortic Valve Stenosis Diseases 0.000 description 1
- 206010002915 Aortic valve incompetence Diseases 0.000 description 1
- 206010002921 Aortitis Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000002102 Atrial Premature Complexes Diseases 0.000 description 1
- 206010003662 Atrial flutter Diseases 0.000 description 1
- 208000006808 Atrioventricular Nodal Reentry Tachycardia Diseases 0.000 description 1
- 239000004156 Azodicarbonamide Substances 0.000 description 1
- AQYFUZRYBJBAGZ-UHFFFAOYSA-N BAY-41-8543 Chemical compound NC1=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC(N)=C1N1CCOCC1 AQYFUZRYBJBAGZ-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Chemical class 0.000 description 1
- 206010048962 Brain oedema Diseases 0.000 description 1
- CLBOSKWOAMJLBF-QAQDUYKDSA-N C=12C(C)(C)C(=O)NC2=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=1N[C@H]1CC[C@H](O)CC1 Chemical compound C=12C(C)(C)C(=O)NC2=NC(C=2C3=CC=CN=C3N(CC=3C(=CC=CC=3)F)N=2)=NC=1N[C@H]1CC[C@H](O)CC1 CLBOSKWOAMJLBF-QAQDUYKDSA-N 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 101100296726 Caenorhabditis elegans pde-5 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007558 Cardiac failure chronic Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000014526 Conduction disease Diseases 0.000 description 1
- 208000002330 Congenital Heart Defects Diseases 0.000 description 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical class OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BWLUMTFWVZZZND-UHFFFAOYSA-N Dibenzylamine Chemical compound C=1C=CC=CC=1CNCC1=CC=CC=C1 BWLUMTFWVZZZND-UHFFFAOYSA-N 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 244000123592 Laurus azorica Species 0.000 description 1
- 206010024119 Left ventricular failure Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 206010027525 Microalbuminuria Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 108020001621 Natriuretic Peptide Proteins 0.000 description 1
- 102000004571 Natriuretic peptide Human genes 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Chemical class OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010039163 Right ventricular failure Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010040639 Sick sinus syndrome Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 description 1
- 206010065342 Supraventricular tachyarrhythmia Diseases 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000018452 Torsade de pointes Diseases 0.000 description 1
- 208000002363 Torsades de Pointes Diseases 0.000 description 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 description 1
- 206010044642 Tricuspid valve stenosis Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000007814 Unstable Angina Diseases 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 206010047289 Ventricular extrasystoles Diseases 0.000 description 1
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 description 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910000288 alkali metal carbonate Inorganic materials 0.000 description 1
- 150000008041 alkali metal carbonates Chemical class 0.000 description 1
- 229910000102 alkali metal hydride Inorganic materials 0.000 description 1
- 150000008046 alkali metal hydrides Chemical class 0.000 description 1
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Chemical class OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000005005 aminopyrimidines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- XOZUGNYVDXMRKW-AATRIKPKSA-N azodicarbonamide Chemical compound NC(=O)\N=N\C(N)=O XOZUGNYVDXMRKW-AATRIKPKSA-N 0.000 description 1
- 235000019399 azodicarbonamide Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical class OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 208000006752 brain edema Diseases 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000003222 cGMP degradation Effects 0.000 description 1
- XQPRBTXUXXVTKB-UHFFFAOYSA-M caesium iodide Chemical compound [I-].[Cs+] XQPRBTXUXXVTKB-UHFFFAOYSA-M 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 206010007625 cardiogenic shock Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 208000028831 congenital heart disease Diseases 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 210000005226 corpus cavernosum Anatomy 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
- 229960002887 deanol Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 125000002720 diazolyl group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- SVABQOITNJTVNJ-UHFFFAOYSA-N diphenyl-2-pyridylphosphine Chemical compound C1=CC=CC=C1P(C=1N=CC=CC=1)C1=CC=CC=C1 SVABQOITNJTVNJ-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 210000005225 erectile tissue Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical class CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- INPKGVRKPSLRFO-UHFFFAOYSA-N ethyl 2-[1-[(2-fluorophenyl)methyl]pyrazolo[3,4-b]pyridin-3-yl]-5-methyl-4,6-dioxo-1,7-dihydropyrrolo[2,3-d]pyrimidine-5-carboxylate Chemical compound N=1C(O)=C2C(C(=O)OCC)(C)C(=O)NC2=NC=1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F INPKGVRKPSLRFO-UHFFFAOYSA-N 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Chemical class 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 229940052308 general anesthetics halogenated hydrocarbons Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000004310 lactic acid Chemical class 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Chemical class 0.000 description 1
- 239000001630 malic acid Chemical class 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000005907 mitral valve insufficiency Diseases 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical class C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 239000000692 natriuretic peptide Substances 0.000 description 1
- 230000007372 neural signaling Effects 0.000 description 1
- 150000002826 nitrites Chemical class 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 238000006053 organic reaction Methods 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000004963 pathophysiological condition Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000004031 phenylhydrazines Chemical class 0.000 description 1
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- BDAWXSQJJCIFIK-UHFFFAOYSA-N potassium methoxide Chemical compound [K+].[O-]C BDAWXSQJJCIFIK-UHFFFAOYSA-N 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 201000011461 pre-eclampsia Diseases 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical class O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 208000015658 resistant hypertension Diseases 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- WXXSNCNJFUAIDG-UHFFFAOYSA-N riociguat Chemical compound N1=C(N)C(N(C)C(=O)OC)=C(N)N=C1C(C1=CC=CN=C11)=NN1CC1=CC=CC=C1F WXXSNCNJFUAIDG-UHFFFAOYSA-N 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000003548 sec-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- ODZPKZBBUMBTMG-UHFFFAOYSA-N sodium amide Chemical compound [NH2-].[Na+] ODZPKZBBUMBTMG-UHFFFAOYSA-N 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 229960000835 tadalafil Drugs 0.000 description 1
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 description 1
- 239000011975 tartaric acid Chemical class 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000006633 tert-butoxycarbonylamino group Chemical group 0.000 description 1
- 125000006318 tert-butyl amino group Chemical group [H]N(*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- QKSQWQOAUQFORH-UHFFFAOYSA-N tert-butyl n-[(2-methylpropan-2-yl)oxycarbonylimino]carbamate Chemical compound CC(C)(C)OC(=O)N=NC(=O)OC(C)(C)C QKSQWQOAUQFORH-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000002537 thrombolytic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003918 triazines Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 1
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
- 230000001196 vasorelaxation Effects 0.000 description 1
- 208000003663 ventricular fibrillation Diseases 0.000 description 1
- 206010047302 ventricular tachycardia Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/527—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Definitions
- the present application relates to novel substituted fused pyrimidines, processes for their preparation, their use alone or in combinations for the treatment and / or prophylaxis of diseases and their use for the preparation of medicaments for the treatment and / or prophylaxis of diseases, in particular for the treatment and / or Prophylaxis of cardiovascular disease.
- cyclic guanosine monophosphate cGMP
- NO nitric oxide
- the guanylate cyclases catalyze the biosynthesis of cGMP from guanosine triphosphate (GTP).
- GTP guanosine triphosphate
- the previously known members of this family can be divided into two groups according to both structural features and the nature of the ligands: the particulate guanylate cyclases stimulable by natriuretic peptides and the soluble guanylate cyclases stimulable by NO.
- the soluble guanylate cyclases consist of two subunits and most likely contain one heme per heterodimer, which is part of the regulatory center. This is central to the activation mechanism. NO can bind to the iron atom of the heme and thus significantly increase the activity of the enzyme. On the other hand, heme-free preparations can not be stimulated by NO. Carbon monoxide (CO) is also able to bind to the central iron atom of the heme, with stimulation by CO being markedly lower than by NO.
- CO Carbon monoxide
- guanylate cyclase plays a crucial role in various physiological processes, in particular in the relaxation and proliferation of smooth muscle cells, platelet aggregation and adhesion, neuronal signaling and diseases based on a disturbance of the above operations.
- the NO / cGMP system may be suppressed, which may, for example, lead to hypertension, platelet activation, increased cell proliferation, endothelial dysfunction, arteriosclerosis, angina pectoris, heart failure, myocardial infarction, thrombosis, stroke and sexual dysfunction.
- a NO-independent treatment option for such diseases which is aimed at influencing the cGMP pathway in organisms, is a promising approach on account of the expected high efficiency and low side effects.
- Bioconversion forms and activates the soluble guanylate cyclase by attack on the central iron atom of the heme.
- tolerance development is one of the major disadvantages of this treatment.
- Phosphodiesterase-5 is the name given to one of the enzymes that cleaves the phosphoric acid ester bond in cGMP to give 5'-guanosine monophosphate (5'-GMP).
- phosphodiesterase-5 occurs predominantly in the smooth muscle of the penile erectile tissue (corpus cavernosum penis) and the pulmonary arteries.
- Blocking cGMP degradation by inhibition of PDE5 leads to increased signals of the relaxation signaling pathways and, in particular, to increased blood supply to the penile corpora and depressurization in the blood vessels of the lung. They are used to treat erectile dysfunction and pulmonary arterial hypertension.
- PDE5 there are other cGMP-cleaving phosphodiesterases (Stasch J.-P. et al., Circulation 2011).
- WO 2010/065275 and WO 2011/149921 disclose substituted pyrrolo and dihydropyridopyrimidines as sGC activators.
- WO 2012/28647 discloses pyrazolopyridines with various azaheterocycles for the treatment of cardiovascular diseases.
- the object of the present invention was to provide new substances which act as stimulators of soluble guanylate cyclase and as stimulators of soluble guanylate cyclase and phosphodiesterase-5 inhibitors (dual principle) and have a similar or improved therapeutic profile compared to the compounds known from the prior art , such as for their in vivo properties, such as their pharmacokinetic and pharmacodynamic behavior and / or their metabolism profile and / or their dose-response relationship.
- the present invention relates to compounds of the general formula (I)
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0, 1 or 2
- M is a bond or (C 1 -C 4) -alkanediyl
- R, R and R 16 are each independently hydrogen
- R and R 15 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6) -alkyl,
- R 15 and R 16 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents 10 from the group cyano, trifluoromethyl, (Ci-C 6 ) -alkyl,
- R 17 is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl
- R 14 and R together with the AtonV (s) to which they are attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents
- R 8A is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl
- R 8B is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or trifluoromethyl, the ring Q is 8- or 9-membered heteroaryl,
- R 3 is -OR 4 or -NR 5 R 6 , where
- R 4 is hydrogen, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl, in which (C 1 -C 6) - Alkyl, (C3-Cv) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl having 1 to 3 substituents independently of one another selected from the group fluorine, difluoromethyl, trifluoromethyl, (Ci-C6) - Alkyl, (C 3 -C 6) -cycloalkyl, difluoromethoxy, trifluoromethoxy,
- R 9, R 10 and R 1 1 are each independently hydrogen, (CI-C ⁇ ) - 5 alkyl or (C3-Cg) -cycloalkyl, where rin (Ci-Ce) -A l ky 1 seine assume negligencemit 1 or 2 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, hydroxyl, (C 1 -C 6) -alkoxy, difluoromethoxy, trifluoro-10-methoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono-
- (Ci-C6) -alkylamino, di- (Ci-C6) -alkylamino and 4- to 7-membered heterocyclyl may be substituted, or
- R 9 and R 10 together with the atom (s) to which they are each attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn has 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, (Ci-C6) alkyl, hydroxy, oxo, (Ci-C6) alkoxy, trifluoromethoxy, (CI-C ⁇ ) - 20 alkoxycarbonyl, amino, mono- (Ci-C6) -alkylamino and
- Di (Ci-C6) alkylamino may be substituted, or
- R 10 and R 11 together with the atom (s) to which they are respectively bonded, form a 4- to 7-membered heterocycle
- R is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, and in which the abovementioned (C 1 -C 12) -alkyl, (C 1 -C 6 ) -alkyl, (C 3 -C -g ) Cycloalkyl-, (C3-C7) -cycloalkyl- and 4- to 7-membered heterocyclyl groups, unless stated otherwise, each independently having 1 to 3 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, ( C 1 -C 4) -alkyl, (C 3 -C 4) -cycloalkyl, hydroxy, difluoromethoxy, trifluoromethoxy, (C 1 -C 4) -alkoxy, hydroxycarbonyl, (C 1 -C 4) -alkoxycarbonyl, amino, phenyl, 4 to 7-membered heterocycly
- R 5 is hydrogen or (C 1 -C 4 ) -alkyl
- R 6 is (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl, in which (C 1 -C 6) -alkyl ( C 3 -C 4) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl having 1 to 3 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 6) -alkyl, ( C3-C7) -cycloalkyl, difluoromethoxy, trifluoromethoxy, oxo, -
- OR 10 , -NR 9 - (C O) -NR 10 R u , -NR 9 -SO 2 -R 10 , -S (O) q -R 12 , -S0 2 -NR 9 R 10 , phenyl, 4 - be substituted to 7-membered heterocyclyl and 5- or 6-membered heteroaryl, wherein p is the number 0 or 1, q is the number 0, 1 or 2,
- R 9 , R 10 and R 11 are each independently hydrogen
- phenyl, 4- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl in turn having 1 to substituents selected independently from the group halogen, cyano, difluoromethyl, trifluoromethyl, (Ci-C 4 ) alkyl, (C 3 - C 7 ) -cycloalkyl, hydroxy, oxo, difluoromethoxy, trifluoromethoxy and (C 1 -C 4) -alkoxy may be substituted, or R 5 and R 6 together with the nitrogen atom to which they are attached form a 4- to 7-membered heterocycle or a 5- or 6-membered heteroaryl wherein the 4- to 7-membered heterocycle and the 5- or 6-membered heterocycle -gliedriges heteroaryl having 1 to 3 substituents independently selected from the group fluorine, cyano, difluoromethyl, trifluoromethyl, (CI-C ⁇ ) -
- R 1 is fluorine, chlorine, cyano, difluoromethyl, trifluoromethyl, (C 1 -C 4 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (C 1 -C 4 ) -alkoxy, n is a number 0, 1 or 2 stands,
- R 2 is trifluoromethyl, (C 1 -C 6) -alkyl, (C 3 -Cg) -cycloalkyl, phenyl or 5- or 6-membered heteroaryl, where (C 1 -C 6) -alkyl having a substituent selected from the group consisting of difluoromethyl and Trifluoromethyl substituted, wherein (Ci-C6) alkyl may be substituted by 1 to 3 substituents fluorine, wherein (C 3 -Cg) cycloalkyl having 1 or 2 substituents independently selected from the group fluorine, methyl and methoxy may be substituted in which phenyl is substituted by 1 to 3 fluorine substituents, where phenyl may be substituted by 1 or 2 substituents independently selected from the group consisting of methyl and methoxy, and wherein 5- and 6-membered heteroaryl may be substituted with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl and methyl,
- Compounds according to the invention are the compounds of the formula (I) and their N-oxides, salts, solvates and solvates of N-oxides and salts, the compounds of the formulas below and their N-oxides, salts, solvates and compounds encompassed by formula (I) Solvates of N-oxides and salts as well as those of formula (I), hereinafter referred to as exemplary compounds and their N-oxides, salts, solvates and solvates of N-oxides and salts, as far as those of formula (I) included , compounds mentioned below are not already N-oxides, salts, solvates and solvates of N-oxides and salts.
- Salts used in the context of the present invention are physiologically acceptable salts of the compounds according to the invention. Also included are salts which are themselves unsuitable for pharmaceutical applications but can be used, for example, for the isolation or purification of the compounds of the invention.
- Physiologically acceptable salts of the compounds of the invention include acid addition salts of mineral acids, carboxylic acids and sulfonic acids, e.g. Salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, formic acid, acetic acid, trifluoroacetic acid, propionic acid, lactic acid, tartaric acid, malic acid, citric acid, fumaric acid, maleic acid and benzoic acid.
- salts of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid formic acid, acetic acid, trifluoro
- Physiologically acceptable salts of the compounds according to the invention also include salts of customary bases, such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts) and ammonium salts derived from ammonia or organic amines having 1 to 16 carbon atoms, such as, by way of example and by way of illustration, ethylamine, diethylamine, triethylamine, ethyldiisopropylamine, monoethanolamine, diethanolamine, triethanolamine, dicyclohexylamine, dimethylaminoethanol, procaine, dibenzylamine, N-methylmorpholine, arginine, lysine, ethylenediamine and N-methylpiperidine.
- customary bases such as, by way of example and by way of preference, alkali metal salts (for example sodium and potassium salts), alkaline earth salts (for example calcium and magnesium salts
- solvates are those forms of the compounds according to the invention which form a complex in the solid or liquid state by coordination with solvent molecules. Hydrates are a special form of solvates that coordinate with water. As solvates, hydrates are preferred in the context of the present invention. "
- the compounds of the invention may exist in different stereoisomeric forms depending on their structure, i. in the form of configurational isomers or optionally also as conformational isomers (enantiomers and / or diastereomers, including those in atropisomers).
- the present invention therefore encompasses the enantiomers and diastereoisomers and their respective mixtures. From such mixtures of enantiomers and / or diastereomers, the stereoisomerically uniform components can be isolated in a known manner; Preferably, chromatographic methods are used for this, in particular HPLC chromatography on achiral or chiral phase.
- the present invention encompasses all tautomeric forms.
- the present invention also includes all suitable isotopic variants of the compounds of the invention.
- An isotopic variant of a compound according to the invention is understood to mean a compound in which at least one atom within the compound according to the invention is exchanged for another atom of the same atomic number but with a different atomic mass than the atomic mass that usually or predominantly occurs in nature.
- isotopes which can be incorporated into a compound of the invention are those of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, chlorine, bromine and iodine, such as 2 H (deuterium), 3 H (tritium), 13 C, 14 C, 15 N, 17 0, 18 0, 32 P, 33 P, 33 S, 34 S, 35 S, 36 S, 18 F, 36 Cl, 82 Br, 123 I, 124 I, 129 I and 131 I.
- Certain isotopic variants of a compound of the invention may be useful, for example, to study the mechanism of action or distribution of drug in the body; Due to the comparatively easy production and detectability, compounds labeled with 3 H or 14 C isotopes are particularly suitable for this purpose.
- the incorporation of isotopes such as deuterium may result in certain therapeutic benefits as a result of greater metabolic stability of the compound, such as prolonging the body's half-life or reducing the required effective dose; Such modifications of the compounds of the invention may therefore optionally also constitute a preferred embodiment of the present invention.
- Isotopic variants of the compounds according to the invention can be prepared by the processes known to the person skilled in the art, for example by the methods described below and the rules given in the exemplary embodiments, by using appropriate isotopic modifications of the respective reagents and / or starting compounds.
- the present invention also includes prodrugs of the compounds of the invention.
- prodrugs refers to compounds which are themselves biologically active or may be inactive, but during their residence time in the body to be converted into compounds of the invention (for example, metabolically or hydrolytically).
- alkyl is a linear or branched alkyl radical having in each case the number of carbon atoms specified.
- alkyl is a linear or branched alkyl radical having in each case the number of carbon atoms specified.
- alkyl is a linear or branched alkyl radical having in each case the number of carbon atoms specified.
- Cycloalkyl or carbocycle in the context of the invention is a monocyclic, saturated alkyl radical having in each case the number of carbon atoms specified. Examples which may be mentioned by way of example include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
- a 5- or 7-membered saturated or partially unsaturated carbocycle is a saturated or partially unsaturated cyclic alkyl radical having in each case the number of carbon atoms specified.
- Examples which may be mentioned by way of example include cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl and cycloheptenyl.
- Alkanediyl in the context of the invention is a linear or branched divalent alkyl radical having 1 to 4 carbon atoms. Examples which may be mentioned are: methylene, ethane-1,2-diyl, ethane-1,1-diyl, propane-1,3-diyl, propane-1,1-diyl, propane-1,2-diyl, propane 2,2-diyl, butane-1,4-diyl, butane-1,2-diyl, butane-l, 3-diyl and butane-2,3-diyl.
- Alkenyl in the context of the invention represents a linear or branched alkenyl radical having 2 to 4 carbon atoms and one double bond.
- alkenyl radical having 2 to 4 carbon atoms and one double bond.
- Alkoxy in the context of the invention is a linear or branched alkoxy radical having 1 to 6 or 1 to 4 carbon atoms.
- Examples include: methoxy, ethoxy, n-propoxy, isopropoxy, 1-methylpropoxy, n-butoxy, iso-butoxy, tert-butoxy, n-pentoxy, iso-pentoxy, 1-ethylpropoxy, 1-methylbutoxy, 2-methylbutoxy , 3-methylbutoxy and n-hexoxy.
- Preference is given to a linear or branched alkoxy radical having 1 to 4 carbon atoms.
- Alkoxycarbonyl in the context of the invention is a linear or branched alkoxy radical having 1 to 4 carbon atoms and an oxygen-bonded carbonyl group.
- methoxycarbonyl methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and tert-butoxycarbonyl.
- Alkoxycarbonylamino in the context of the invention represents an amino group having a linear or branched alkoxycarbonyl substituent which has 1 to 4 carbon atoms in the alkyl chain and is linked via the carbonyl group to the nitrogen atom.
- alkoxycarbonylamino represents an amino group having a linear or branched alkoxycarbonyl substituent which has 1 to 4 carbon atoms in the alkyl chain and is linked via the carbonyl group to the nitrogen atom.
- Mono-alkylamino in the context of the invention represents an amino group having a linear or branched alkyl substituent which has 1 to 6 carbon atoms.
- methylamino, ethylamino, n-propylamino, isopropylamino and tert-butylamino By way of example and preferably mention may be made of: methylamino, ethylamino, n-propylamino, isopropylamino and tert-butylamino.
- Di-alkylamino in the context of the invention represents an amino group having two identical or different linear or branched alkyl substituents, each having 1 to 6 carbon atoms. Examples which may be mentioned are: N, N-dimethylamino, N, N-diethylamino, N-ethyl-N-methylamino, N-methyl-Nn-propylamino, N-isopropyl-Nn-propylamino, N-tert-butyl-N-methylamino, N Ethyl-Nn-pentylamino and Nn-hexyl-N-methylamino.
- 5- to 7-membered saturated or partially unsaturated Heterocvclus in the context of the invention for a saturated or partially unsaturated heterocycle having a total of 5 to 7 ring atoms, which contains a ring heteroatoms from the series ⁇ , O, S, SO and / or SO2 ,
- Examples include: pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl, dihydropyrrolyl, dihydropyridyl.
- Heterocyclic or heterocyclic stands in the context of the invention for a saturated heterocycle having a total of 4 to 7 ring atoms, which contains one or two ring heteroatoms from the series ⁇ , O, S, SO and / or SO 2 .
- Examples which may be mentioned are: azetidinyl, oxetanyl, pyrrolidinyl, pyrazolidinyl, imidazolinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl and Dioxidothiomorpholinyl.
- Preferred are azetidinyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, tetrahydropyranyl and morpholinyl.
- 5- or 6-membered heteroaryl is in the context of the invention for a monocyclic aromatic heterocycle (heteroaromatic) with a total of 5 or 6 ring atoms, which contains up to three identical or different ring heteroatoms from the series ⁇ , O and / or S. a ring carbon atom or optionally linked via a ring nitrogen atom.
- furyl By way of example and by way of preference: furyl, pyrrolyl, thienyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isoxazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl, pyrimidinyl, Pyridazinyl, pyrazinyl and triazinyl.
- 8- or 9-membered heteroaryl is in the context of the invention for a bicyclic aromatic or partially unsaturated heterocycle having a total of 8 or 9 ring atoms, the at least two nitrogen atoms and up to two further, identical or different ring heteroatoms from the series N, O and / or S contains.
- Examples which may be mentioned are: dihydrothienopyrazolyl, thieno pyrazolyl, pyrazolopyrazolyl, imidazothiazolyl, tetrahydrocyclopentapyrazolyl, dihydrocyclopentapyrazolyl, tetrahydroindazolyl, dihydroindazolyl, indazolyl, pyrazolopyridyl, tetrahydropyrazolopyridyl, pyrazolopyrimidinyl, imidazopyridyl and imidazopyridazinyl.
- Preference is given to indazolyl, pyrazolo [3,4-b] pyridyl, pyrazolo [3,4-b] pyrimidinyl and imidazo [l, 5-a] pyridyl.
- Halogen is in the context of the invention for fluorine, chlorine, bromine and iodine. Preference is given to bromine and iodine.
- An oxo group in the context of the invention is an oxygen atom which is bonded via a double bond to a carbon atom.
- a thiooxo group in the context of the invention represents a sulfur atom which is bonded via a double bond to a carbon atom.
- radicals are substituted in the compounds according to the invention, the radicals can, unless otherwise specified, be monosubstituted or polysubstituted. In the context of the present invention, the meaning is independent of each other for all radicals which occur repeatedly. Substitution with one, two or three identical or different substituents is preferred.
- the term “treatment” or “treating” includes inhibiting, delaying, arresting, alleviating, attenuating, restraining, reducing, suppressing, restraining or curing a disease, a disease, a disease, an injury or a medical condition , the unfolding, the course or progression of such conditions and / or the symptoms of such conditions.
- the term “therapy” is understood to be synonymous with the term “treatment”.
- prevention means prevention, prophylaxis or "prevention” are used synonymously in the context of the present invention and designate the avoidance or reduction of the risk 1 r
- the treatment or prevention of a disease, a disease, a disease, an injury or a health disorder can be partial or complete.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0, 1 or 2
- R 7A is hydrogen, fluorine, (Ci-C i) -alkyl, hydroxy or amino, wherein (Ci-C i) -alkyl having 1 to 3 substituents independently of one another selected from the group fluorine, trifluoromethyl, hydroxy, hydroxycarbonyl, ( C1-C4) - alkoxycarbonyl and amino may be substituted,
- R 7B is hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 6 ) -alkyl, (C 1 -C 4) -alkoxycarbonylamino, cyano, (C 3 -C 4) -cycloalkyl, difluoromethoxy, trifluoromethoxy, phenyl or a group of the formula -MR 13 in which (C 1 -C 6) -alkyl having 1 to 3 substituents selected independently of one another from the group of fluorine, cyano, trifluoromethyl, (C 3 -C 4) -cycloalkyl, hydroxy,
- Difluoromethoxy, trifluoromethoxy, (Ci-C i) alkoxy, hydroxycarbonyl, (C 1 -C 4) - alkoxycarbonyl and amino may be substituted, and wherein
- M is a bond or (C 1 -C 4) -alkanediyl
- - (C O) r -NR 14 R 15
- R 17 , -NR 14 - (C O) -NR 15 R 16 , -NR 14 -SO 2 -NR 15 R 16 , -NR 14 -SO 2 -R 17 , -S (O) s - R 17 , -SO 2 -NR 14 R 15 , 4- to 7-membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl, where r is the number 0 or 1, s is the number 0, 1 or 2,
- R 14 , R 15 and R 16 are each independently hydrogen
- R 14 and R 15 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and di - (Ci-C6) -alkylamino, or
- R 15 and R 16 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6 ) -alkyl, hydroxy, oxo, (C 1 -C 6 ) -alkoxy, trifluoromethoxy, (C 1 -C 6 ) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and Di- (Ci-C6) -alkylamino may be substituted,
- R 17 is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, or
- R 14 and R 17 together with the atom (s) to which they are respectively attached, form a 4- to 7-membered heterocycle, in which the 4- to 7-membered heterocycle in turn contains 1 or 2 substituents independently of one another selected from the group consisting of cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, C ⁇ ) - alkoxycarbonyl, amino, mono- (Ci-C6) -alkylamino and
- Heterocyclyl and 5- or 6-membered heteroaryl may be substituted, or
- R 7A and R 7B together with the carbon atom to which they are attached, a
- R 8A represents hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl, represents hydrogen, fluorine, (C 1 -C 4) -alkyl or trifluoromethyl, the ring Q represents 8- or 9-membered heteroaryl, 4 or -NR 5 R 6 ,
- R 9 , R 10 and R 11 are each independently hydrogen, (CI-C ⁇ ) -alkyl or (C3-Cg) -cycloalkyl, where rin (Ci-Ce) -Al ky 1 in turn with 1 or 2 substituents independently selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, hydroxy, (C 1 -C 6) -alkoxy, difluoromethoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino, and di (C 1 -C 6 -alkyl) ) -alkylamino and 4- to 7-membered heterocyclyl, or
- R 9 and R 10 together with the atom (s) to which they are respectively attached, form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group fluorine, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (CI-C ⁇ ) - Alkoxycarbonyl, amino, mono- (Ci-C6) -alkylamino and di- (Ci-C6) -alkylamino may be substituted, or
- R 10 and R 11 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group fluorine, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and di - (Ci-C6) -alkylamino, and in which
- R 12 is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, and wherein the aforementioned (C 1 -C 4 ) -alkyl, (C 1 -C 6 ) -alkyl, (C 3 -C-C ) -Cycloalkyl- and 4- to 7-membered heterocyclyl groups, unless stated otherwise, each independently having 1 to 3 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, (C3-Cv) -cycloalkyl, hydroxy, difluoro - methoxy, trifluoromethoxy, (C 1 -C 4) -alkoxy, hydroxycarbonyl, (C 1 -C 4) -alkoxycarbonyl, amino, phenyl, 4- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl may be substituted,
- R 5 is hydrogen or (C 1 -C 4 ) -alkyl
- R 6 is (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl, in which (C 1 -C 6) -alkyl ( C 3 -C 4) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl having 1 to 3 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 6) -alkyl, ( C3-C7) -cycloalkyl, difluoromethoxy, trifluoromethoxy, oxo, -
- - 21 - to 7-membered heterocyclyl and 5- or 6-membered heteroaryl may be substituted, wherein p is the number 0 or 1, q is the number 0, 1 or 2,
- R 9 , R 10 and R u are each independently hydrogen
- Cv) -cycloalkyl, difluoromethoxy, trifluoromethoxy and (Ci-C i) -alkoxy may be substituted, or
- R 9 and R 10 together with the atom (s) to which they are respectively attached, form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group fluorine, cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkyl - Amino and di- (Ci-C6) -alkylamino may be substituted, or
- R 10 and R 11 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and di - (C 1 -C 6) -alkylamino may be substituted, in which (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
- phenyl, 4- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl in turn having 1 to substituents selected independently from the group halogen, cyano, difluoromethyl, trifluoromethyl, (Ci-C 4 ) alkyl, (C 3 - C 7 ) -cycloalkyl, hydroxy, oxo, difluoromethoxy, trifluoromethoxy and (C 1 -C 4) -alkoxy, or R 5 and R 6 together with the nitrogen atom to which they are attached form one
- R is trifluoromethyl, (C 1 -C 6) -alkyl, (C 3 -C 6) -cycloalkyl, phenyl or 5- or 6-membered heteroaryl, ""
- (C 1 -C 6) -alkyl is substituted by one substituent selected from the group consisting of difluoromethyl and trifluoromethyl, where (C 1 -C 6) -alkyl can be substituted by 1 to 3 substituents of fluorine, where (C 3 -C 6) -cycloalkyl may be substituted with 1 or 2 substituents independently selected from the group fluorine, methyl and methoxy, wherein phenyl is substituted by 1 to 3 substituents fluorine, wherein phenyl may be substituted with 1 or 2 substituents independently selected from the group of methyl and methoxy and wherein 5- and 6-membered heteroaryl having 1 or 2 substituents independently of one another selected from the group of fluorine, trifluoromethyl and methyl may be substituted, and their N-oxides, salts, solvates, salts of N-oxides and solvates of N-oxides Oxides and salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # l represents the point of attachment to the carbonyl group
- # 2 represents the point of attachment to the pyrimidine ring
- m is a number 0 or 1
- R 7A is hydrogen, fluorine, methyl, ethyl, hydroxy or amino
- R 7B is hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 4 ) -alkyl, methoxycarbonylamino, cyano, cyclopropyl, cyclobutyl, cyclopentyl, phenyl or a group of the formula -MR 13 , in which (C 1 -C 10) -alkyl having 1 to 3 substituents independently of one another selected from the group consisting of fluoro, cyano, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy,
- R 14 and R 15 are each independently hydrogen, methyl,
- Ethyl iso -propyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl or pyridyl, wherein methyl, ethyl and iso-propyl are further independently 1 or 2 substituents selected from among fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl and amino, and in which oxadiazolonyl, oxadiazolethionyl, phen
- cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl or tetrahydropyranyl ring in which the cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl and tetrahydropyranyl ring may be substituted with 1 or 2 substituents independently of one another selected from the group of fluorine and methyl, for hydrogen, fluorine, methyl, Is ethyl or hydroxy, is hydrogen, fluorine, methyl, ethyl or trifluoromethyl, the ring Q is a group of the formula
- ** represents the point of attachment to the pyrimidine, the ring Qi together with the atoms to which it is attached forms a 5- to 7-membered saturated or partially unsaturated carbocycle or a 5- to 7-membered saturated or partially unsaturated heterocycle .
- R 1 is fluoro, chloro or methyl
- n is a number 0, 1 or 2
- a 1 , A 2 , A 3 and A 4 are each independently N, CH or CR 1 , with the proviso that maximum two of the groups A 1 , A 2 , A 3 and A 4 are N,
- R 3 is -OR 4 or -NR 5 R 6 , where
- R and R are each independently hydrogen, methyl
- R 9 and R 10 together with the atom (s) to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl , Piperazinyl- and morpholinyl ring in turn may be substituted with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, for hydrogen Is methyl or ethyl, (C 1 -C 6) -alkyl, cyclopropyl, (C 3 -C 6) -cycloalkyl, oxetanyl, azetidinyl, tetrahydr
- P is the number 0 or 1
- R 9 and R 10 are each independently hydrogen, methyl
- R 9 and R 10 together with the atom (s) to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl , Piperazinyl and morpholinyl ring in turn with 1 or 2 Substituents independently selected from the
- Fluorine trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, or
- R 2 is trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoroprop-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl , Pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein phenyl is substituted by 1 to 3 substituents fluorine, and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl may be substituted by 1 or 2 substituents fluorine, and their Salts, solvates and solvates of salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, which is the point of attachment to the carbonyl group, is the point of attachment to the pyrimidine ring, a number 0 or 1, is hydrogen, fluorine, methyl, ethyl, hydroxy or amino, is hydrogen, fluorine, difluoromethyl, trifluoromethyl, (Ci-C i) alkyl, methoxycarbonylamino, Cyano, cyclopropyl, cyclobutyl, cyclopentyl, phenyl or a group of the formula -MR 13 , wherein (Ci-C i) alkyl having 1 to 3 substituents independently selected from the group fluorine, cyano, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl , Hydroxy, difluoromethoxy, tri
- M is a bond or methylene
- R 14 and R 15 are each independently hydrogen, methyl,
- Ethyl iso -propyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl or pyridyl, wherein methyl, ethyl and iso-propyl are further independently 1 or 2 substituents selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl and amino may be substituted, and wherein oxadiazolonyl, oxadiazol
- R 7A and R 7B together with the carbon atom to which they are attached, a
- R 8A is hydrogen, fluorine, methyl, ethyl or hydroxy
- R 8B is hydrogen, fluorine, methyl, ethyl or trifluoromethyl, the ring Q is a group of the formula
- ** represents the point of attachment to the pyrimidine, the ring Qi together with the atoms to which it is attached forms a 5- to 7-membered saturated or partially unsaturated carbocycle or a 5- to 7-membered saturated or partially unsaturated heterocycle , R 1 is fluorine, chlorine or methyl, n is a number 0, 1 or 2,
- a 1 , A 2 , A 3 and A 4 are each independently N, CH or CR 1 , with the proviso that at most two of the groups A 1 , A 2 , A 3 and A 4 are N,
- R 3 is -OR 4 or -NR 5 R 6 , wherein (Ci-C6) alkyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl in which (C 1 -C 6) -alkyl having 1 to 3 substituents independently of one another is selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, difluoromethoxy, trifluoromethoxy,
- R and R together with the atom (s) to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl - And morpholinyl ring in turn with 1 or 2 substituents independently selected from the Group fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino may be substituted, is hydrogen, methyl or ethyl, for (Ci-C6) alkyl, cyclopropyl, cyclobutyl , Cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrol
- R 9 and R 10 are each independently hydrogen, methyl, ethyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1, 1, 2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl or cyclopentyl, or
- R 9 and R 10 together with the atom (s) to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl , Piperazinyl- and Morpholinyl ring in turn may be substituted with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, or
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0
- R 7A is hydrogen, fluorine, methyl, ethyl, hydroxy or amino
- R 7B is hydrogen, fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, methoxycarbonylammo, cyclopropyl, cyclobutyl, cyclopentyl, or a group of the formula -MR 13 , in which methyl and ethyl having 1 to 3 substituents independently of one another are selected from the group consisting of fluorine, Cyano, trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl and amino, and wherein
- R 15 is phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl or pyrimidinyl, in which r is the number 1,
- R 14 and R 15 are each independently hydrogen or
- Cyclopropyl and in which phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and pyrimidinyl are in turn selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, isopropyl, 2,2,2-trifluoroethyl, 1, 1, with 1 or 2 substituents independently of one another 2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl, cyclopropylmetyl and cyclobutylmethyl may be substituted, or
- R 7A and R 7B together with the carbon atom to which they are attached, a
- R lc is hydrogen or chlorine
- a 1 is N or CH
- a 3 is N, CH or CF
- R 9 and R 10 are each independently hydrogen, or
- pyrazolyl having 1 or 2 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl, cyclopentyl is hydrogen, methyl or ethyl, (C 1 -C 6) -alkyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl , Pyridyl or pyrimidinyl, in which (C 1 -C 6) -alkyl having 1
- Ethyl trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2,2-pentafluoroethyl, cyclopropyl or cyclobutyl, and wherein tetrahydro furanyl, pyrrolidinyl, tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl in turn with 1 or
- substituents independently of one another can be selected from the group of fluorine, chlorine, cyano, difluoromethyl, trifluoromethyl, methyl, ethyl and oxo, in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl .
- Triazolyl, oxadiazolyl, thiadiazolyl, pyridyl and pyrimidinyl having 1 or 2 substituents independently selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl and oxo, or R 5 and R 6 together with the nitrogen atom to which they are attached are, one
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # represents the point of attachment to the carbonyl group which is connected to the pyrimidine ring
- m is a number
- R 7A is hydrogen, fluorine, methyl or hydroxy
- R 7B is hydrogen, fluorine, trifluoromethyl, 2,2,2-trifluoroethyl or methyl, the ring Q is a group of the formula
- R la is hydrogen or methyl
- R lb is hydrogen or fluorine
- R lc is hydrogen or chlorine
- a 1 is N or CH 3
- a 3 is N, CH or CF
- R 3 is -OR 4 or -NR 5 R 6 , wherein
- R 9 and R 10 are each independently hydrogen or
- Methyl and wherein pyrazolyl having 1 or 2 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl, cyclopentyl may be substituted
- R 5 is hydrogen, methyl or ethyl
- Ethyl trifluoromethyl, 2,2,2-trifluoroethyl, 1, 1, 2,2,2-pentafluoroethyl, cyclopropyl or cyclobutyl, and wherein tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl in turn with 1 or
- substituents independently of one another can be selected from the group of fluorine, chlorine, cyano, difluoromethyl, trifluoromethyl, methyl, ethyl and oxo, in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl .
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0
- R 7A is hydrogen, fluorine, methyl or hydroxy
- R 7B is hydrogen, fluorine, trifluoromethyl, methyl or 2,2,2-trifluoroethyl, or R 7A and R 7B together with the carbon atom to which they are attached, a
- R 1b is hydrogen or fluorine
- R lc is hydrogen or chlorine, N is or CH, A 3 is N, CH or CF, is -NR 5 R 6 , wherein
- R is hydrogen
- R 9 is hydrogen
- R is 2-fluorophenyl, 2,3-difluorophenyl or 3-fluoropyrid-2-yl, and their salts, solvates and solvates of the salts.
- R is 2-fluorophenyl, 2,3-difluorophenyl or 3-fluoropyrid-2-yl, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number
- R 7A is methyl
- R 7B is methyl
- ring Q is a group of the formula
- R la is hydrogen or methyl
- R lb is hydrogen or fluorine, is hydrogen or chlorine, is N or CH, is N, CH or CF, is -NR 5 R 6 , wherein
- R 5 is hydrogen, methyl or ethyl
- P is the number 0 or 1
- R 9 and R are each independently hydrogen, methyl
- Ethyl trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl or cyclobutyl, and wherein tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl in turn with 1 or ⁇
- substituents independently of one another can be selected from the group of fluorine, chlorine, cyano, difluoromethyl, trifluoromethyl, methyl, ethyl and oxo, in which oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl .
- Triazolyl, oxadiazolyl, thiadiazolyl, pyridyl and pyrimidinyl having 1 or 2 substituents independently selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl and oxo, or R 5 and R 6 together with the nitrogen atom to which they are attached are, one
- R 2 is 3,3,3-trifluoroprop-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, phenyl or pyridyl, wherein phenyl is substituted with 1 to 3 fluorine substituents, and wherein pyridyl with 1 substituent fluorine may be substituted, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where _
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0
- R 7A is hydrogen, fluorine, methyl, hydroxy
- R 7B is hydrogen, fluorine, methyl or trifluoromethyl, or
- R 7A and R 7B together with the carbon atom to which they are attached
- R 9 and R 10 are each independently hydrogen or
- pyrazolyl having 1 or 2 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl, cyclopentyl is hydrogen, methyl or ethyl, (C 1 -C 6) -alkyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl , Pyridyl or pyrimidinyl, in which (C 1 -C 6) -alkyl having 1
- R 9 and R 10 are each independently hydrogen, methyl
- R 2 is 2-fluorophenyl, 2,3-difluorophenyl or 3-fluoropyrid-2-yl, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # l represents the point of attachment to the carbonyl group, which is the point of attachment to the pyrimidine ring
- m is a number 0, 1 or 2
- R is hydrogen, fluorine, (Ci-C i) -alkyl, hydroxy or amino, in which (C 1 -C 10) -alkyl having 1 to 3 substituents selected independently of one another from the group of fluorine, trifluoromethyl, hydroxyl, hydroxycarbonyl, (C 1 -C 4 ) -alkoxycarbonyl and amino may be substituted,
- R 7B is hydrogen, fluorine, (C 1 -C 4 ) -alkyl, trifluoromethyl, (C 1 -C 4 ) -alkoxycarbonyl-amino or phenyl, where (C 1 -C 4) -alkyl having 1 to 3 substituents is selected independently of one another the group fluorine, trifluoromethyl, hydroxy, hydroxycarbonyl, (C1-C4) - alkoxycarbonyl and amino may be substituted, or
- R 7A and R 7B together with the carbon atom to which they are attached, a
- R 8A is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl
- R 8B is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or trifluoromethyl, the ring Q is 8- or 9-membered heteroaryl,
- R 3 is -OR 4 or -NR 5 R 6 , where
- R 9 , R 10 and R u are each independently hydrogen
- Substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, hydroxy, (Ci-C6) alkoxy, difluoromethoxy, trifluoromethoxy, (CI-C ⁇ ) - alkoxy ⁇
- R 9 and R 10 together with the atom (s) to which they are each attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn has 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, (Ci-C6) alkyl, hydroxy, oxo, (Ci-C6) alkoxy, trifluoromethoxy, (CI-C ⁇ ) - 20 alkoxycarbonyl, amino, mono- (Ci-C6) -alkylamino and
- Di (Ci-C6) alkylamino may be substituted, or
- R 10 and R 11 together with the atom (s) to which they are respectively bonded form a 4- to 7-membered heterocycle
- di- (Ci-C6) -alkylamino may be substituted, and wherein is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl,
- R 5 is hydrogen or (C 1 -C 4 ) -alkyl
- R 9 , R 10 and R 11 independently of one another are each hydrogen
- R 9 and R 10 together with the atom (s) to which they are respectively attached, form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and di - (Ci-C6) -alkylamino, or
- R 10 and R 11 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6) -alkyl,
- R 12 is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, or
- 4- to 7-membered heterocycle wherein the 4- to 7-membered heterocycle having 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, (Ci-C6) alkyl, hydroxy, oxo, (Ci-C6) - Alkoxy, trifluoromethoxy, (Ci-C6) alkoxycarbonyl, amino, mono- (Ci-C6) -alkylamino and di- (Ci-C6) -alkylamino may be substituted,
- R 1 is fluorine, chlorine or methyl, n is a number 0, 1 or 2,
- R 2 is (Ci-C6) -alkyl, (C3-Cg) -cycloalkyl, phenyl or 5- or 6-membered heteroaryl, wherein (Ci-C6) -alkyl is substituted with a substituent trifluoromethyl, wherein (Ci-C6 ) Alkyl having 1 to 3 substituents fluorine, wherein phenyl is substituted by 1 to 3 substituents fluorine, and wherein 5- and 6-membered heteroaryl may be substituted with 1 or 2 substituents independently selected from the group fluorine and methyl , and their N-oxides, salts, solvates, salts of N-oxides and solvates of N-oxides and salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where the attachment site is the carbonyl group, the attachment site is the pyrimidine ring, m is a number 0 or 1,
- R 7A is hydrogen, fluorine, methyl, ethyl or hydroxy
- R 7B is hydrogen, fluorine, methyl, ethyl, trifluoromethyl, methoxycarbonylammo or phenyl, wherein methyl and ethyl may be substituted with 1 to 3 substituents independently selected from the group fluorine, trifluoromethyl and hydroxy, or
- R 7A and R 7B together with the carbon atom to which they are attached, a
- R 8A is hydrogen, fluorine, methyl, ethyl or hydroxy, is hydrogen, fluorine, methyl, ethyl or trifluoromethyl, the ring Q is a group of the formula
- R 1 is fluorine, chlorine or methyl
- n is a number 0, 1 or 2
- a 1 , A 2 , A 3 and A 4 are each independently N, CH or CR 1 , with the proviso that at most two of the groups A 1 , A 2 , A 3 and A 4 are N, for -OR 4 or -NR 5 R 6 ,
- R 9 and R 10 are each independently hydrogen, methyl or ethyl, or
- R 9 and R 10 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and Morpholinyl ring in turn having 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy,
- Oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino may be substituted
- R 5 is hydrogen or methyl
- Substituents independently selected from the group of fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino may be substituted, or
- R 2 is trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoroprop-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl , Pyridyl, pyrimidinyl,
- Pyrazinyl or pyridazinyl wherein phenyl is substituted by 1 to 3 substituents fluorine, and wherein pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl may be substituted by 1 or 2 substituents fluorine, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where # 1 is the point of attachment to the carbonyl group, # 2 is the point of attachment to the pyrimidine ring, m is a number 0,
- R 7A is hydrogen, fluorine, methyl or hydroxy
- R 7B is hydrogen, fluorine, methyl or trifluoromethyl, or
- R 7A and R 7B together with the carbon atom to which they are attached, a
- ** is the point of attachment to the pyrimidine
- R la is hydrogen or fluorine
- R lb is hydrogen or methyl
- R 3 is -OR 4 or -NR 5 R 6 , wherein
- R 4 is hydrogen or (C 1 -C 6 ) -alkyl, ⁇
- R 9 and R 10 are each independently hydrogen
- R 5 is hydrogen
- R 6 is (C 1 -C 6 ) -alkyl, in which (C 1 -C 6 ) -alkyl having 1 or 2 substituents selected independently of one another from the group of fluorine, difluoromethyl, trifluoromethyl, difluoromethoxy,
- R 9 and R 10 are each independently hydrogen, R 2 is 2,2,3,3,3-pentafluoroprop-1-yl, 2-fluorophenyl or 2,3,6-trifluorophenyl, and their salts, solvates and Solvates of salts.
- R 3 is -OR 4 or -NR 5 R 6 , where
- R 9 and R 10 are each independently hydrogen, methyl or ethyl, or
- R 9 and R 10 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and Morpholinyl ring in turn having 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy,
- Oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino may be substituted
- R 5 is hydrogen or methyl
- R 9 and R 10 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and Morpholinyl ring in turn having 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy, _
- Oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino may be substituted, or
- Ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl ring, in turn, having 1 or 2 substituents selected independently from the group of fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, Methylamino, ethylamino, dimethylamino and diethylamino, n, L, Q, R 1 and R 2 are each as defined above, and their salts, solvates and solvates of the salts.
- R 3 is -NR 5 R 6 , where
- R 5 is hydrogen or methyl
- R 9 and R 10 are each independently hydrogen, methyl or ethyl, or _
- R 9 and R 10 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and Morpholinyl ring in turn with 1 or 2
- Substituents independently selected from the group of fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino may be substituted, or
- Azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or Morpholinyl- ring wherein the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl ring in turn with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl , Ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, n, L, Q, R 1 and R 2 each have the meanings given above, and their salts, solvates and solvates of salts.
- R 3 is -NR 5 R 6 , where R 5 is hydrogen or methyl
- R 9 and R 10 are each independently hydrogen, methyl or ethyl, or
- R 9 and R 10 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and Morpholinyl ring in turn may be substituted with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, or
- Azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or Morpholinyl- ring wherein the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl ring in turn with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl , Ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, n, L, Q, R 1 and R 2 each have the meanings given above, and their salts, solvates and solvates of salts.
- a 1 , A 3 and A 4 are each independently N, CH or CR 1 , wherein
- R 1 is fluorine, chlorine or methyl
- n is a number 0, 1 or 2, with the proviso that at most two of the groups A 1 , A 3 and A 4 are N
- R 3 is -NR 5 R 6 stands, where
- R 5 is hydrogen or methyl
- R 6 is (C 1 -C 6 ) -alkyl, in which (C 1 -C 6 ) -alkyl having 1 or 2 substituents independently of one another is selected from the group consisting of fluorine, difluoromethyl and trifluoromethyl,
- R 5 is hydrogen or methyl
- R 6 is (C 1 -C 6 ) -alkyl, in which (C 1 -C 6 ) -alkyl having 1 or 2 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl and trifluoromethyl, is 2-fluorophenyl or 3-fluoropyride -2-yl stands, and
- R 3 is -NR 5 R 6 , where
- R 5 is hydrogen or methyl
- R 6 is (C 1 -C 6 ) -alkyl wherein (C 1 -C 6 ) -alkyl having 1 or 2 substituents independently of one another is selected from the group consisting of fluorine, difluoromethyl and trifluoromethyl, n, L, Q, R 1 and R 2 each have the meanings given above, and their salts, solvates and solvates of the salts.
- R 3 is -NR 5 R 6 , where
- R 5 is hydrogen or methyl
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number
- R 7A is methyl
- R 7B is methyl, R 3 is -NR 5 R 6 , wherein
- R 5 is hydrogen or methyl
- R 9 is hydrogen, n, Q, R 1 and R 2 are each as defined above, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 represents the point of attachment to the carbonyl group
- # 2 represents the point of attachment to the pyrimidine ring
- m stands for a number 0
- R 7A is hydrogen, fluorine, methyl or hydroxy
- R 7B is hydrogen, fluorine, methyl or trifluoromethyl
- R 3 is -NR 5 R 6 , where
- R 5 is hydrogen or methyl
- R 9 is hydrogen, n, Q, R 1 and R 2 are each as defined above, and their salts, solvates and solvates of the salts.
- R 9 and R 10 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and Morpholinyl ring may in turn be substituted with 1 or 2 substituents independently of one another selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, n, L, Q R 1 and R 2 each have the meanings given above, and their salts, solvates and solvates of the salts.
- R is -OR 4 , where
- R 4 is hydrogen, n, L, Q, R 1 and R 2 are each as defined above, and their salts, solvates and solvates of the salts.
- R 4 is hydrogen, n, L, Q, R 1 and R 2 are each as defined above, and their salts, solvates and solvates of the salts.
- R 2 is 2,2,3,3,3-pentafluoroprop-1-yl, 2-fluorophenyl, 2,3-difluorophenyl, 2,3,6-trifluorophenyl, 3-fluoropyrid-2-yl or pyrimidin-2-yl and their salts, solvates and solvates of the salts.
- R 2 is 2-fluorophenyl or 3-fluoropyrid-2-yl, and their salts, solvates and solvates of the salts.
- R 2 is 2-fluorophenyl or 3-fluoropyrid-2-yl, and their salts, solvates and solvates of the salts.
- particular preference is also given to compounds of the formula (I) in which
- R 2 is 2-fluorophenyl, and their salts, solvates and solvates of the salts.
- R 2 is 3-fluoropyrid-2-yl or pyrimidin-2-yl, and their salts, solvates and solvates of the salts.
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number
- R 7A is hydrogen, fluoro, methyl or hydroxy
- R 7B is hydrogen, fluorine, methyl or trifluoromethyl, or
- R 7A and R 7B together with the carbon atom to which they are attached, a
- cyclopropyl and the cyclobutyl ring with 1 o of the 2 substituents can be independently selected from the group fluorine and methyl, n, Q, R 1 , R 2 and R 3 are each as defined above, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where # l is the point of attachment to the carbonyl group,
- # 2 represents the point of attachment to the pyrimidine ring
- m is a number 1
- R 7A is hydrogen, fluorine, methyl or hydroxy
- R 7B is hydrogen, fluorine, methyl or trifluoromethyl
- n, Q, R 1 , R 2 and R 3 are each as defined above, and their salts, solvates and solvates salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # l represents the point of attachment to the carbonyl group
- # 2 represents the point of attachment to the pyrimidine ring
- m is a number 1
- R 7A is methyl
- R 7B is methyl
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number
- R 7A is methyl
- R 7B is methyl, or
- R 7A and R 7B together with the carbon atom to which they are attached, a
- Form tetrahydrofuranyl ring, n, Q, R 1 , R 2 and R 3 each have the meanings given above, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0
- R 7A is hydrogen, fluorine, methyl, ethyl, hydroxy or amino
- R is a group of the formula -MR, in which
- R 15 is phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl or pyrimidinyl, in which r is the number 1,
- R 14 and R 15 are each independently hydrogen or
- Cyclopropyl and in which phenyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl and pyrimidinyl themselves with 1 or 2 substituents independently of one another selected from the group fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, iso-propyl, 2,2,2-trifluoroethyl, 1, 1, 2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl, cyclopropylmetyl and cyclobutylmethyl may be substituted, and their salts, solvates and solvates of the salts.
- R 3 is -NR 5 R 6 , where
- R 5 is hydrogen or methyl
- R 9 and R 10 are each independently hydrogen, methyl or ethyl, or
- R 9 and R 10 together with the nitrogen atom to which they are attached form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and Morpholinyl ring in turn may be substituted with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, or
- Azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or Morpholinyl- ring wherein the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl ring in turn with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, methyl , Ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino, the ring Q may be a group of the formula
- attachment site is -CH 2 -R, where the point of attachment to the pyrimidine is A, A and A are each independently N, CH or CR, wherein
- R 1 is fluorine, chlorine or methyl
- n is a number 0, 1 or 2
- n is a number 0, 1 or 2
- attachment site is -CH 2 -R, where the point of attachment to the pyrimidine is A, A and A are each independently N, CH or CR, wherein
- R 1 is fluoro, chloro or methyl
- R 5 is hydrogen
- a 1 , A 3 and A 4 are each independently N, CH or CR 1 , wherein
- R 1 is fluorine, chlorine or methyl
- n is a number 0, 1 or 2
- n is a number 0, 1 or 2
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0
- R 7A is hydrogen, fluorine, methyl or hydroxy
- R 7B is hydrogen, fluorine, trifluoromethyl, 2,2,2-trifluoroethyl or methyl
- the ring Q is a group of the formula
- R is hydrogen or fluorine, is hydrogen or chlorine, is N or CH, is N, CH or C-F, R and R have the meanings given above, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # l represents the point of attachment to the carbonyl group
- # is the point of attachment to the pyrimidine ring
- m is a number 0 or 1
- is hydrogen, fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl, methoxycarbonylammo, cyclopropyl, cyclobutyl, cyclopentyl, or a group of the formula -MR 13 , where methyl and ethyl having 1 to 3 substituents independently of one another selected from the group fluorine, cyano, Trifluoromethyl, cyclopropyl, cyclobutyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxycarbonyl, methoxycarbonyl, ethoxycarbonyl and amino, and wherein is a bond, for - (C O) r -NR 14 R 15 , phenyl, Thiazoly
- R 7A and R 7B together with the carbon atom to which they are attached, a
- Form pyrrolidinyl or tetrahydropyranyl ring in which the cyclopropyl, cyclobutyl, cyclopentyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl and tetrahydropyranyl ring may be substituted with 1 or 2 substituents independently selected from the group of fluorine and methyl, R 8A is hydrogen, fluorine, methyl or hydroxy,
- R 8B is hydrogen, fluorine, methyl or trifluoromethyl, the ring Q is a group of the formula
- R la is hydrogen or methyl
- R lb is hydrogen or fluorine
- R lc is hydrogen or chlorine
- a 1 is N or CH is A 3 is N, CH or CF
- R 2 and R 3 each have the meanings given above, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # Denotes the point of attachment to the pyrimidine ring, m is a number 0, 1 or 2,
- R 7A is hydrogen, fluorine, (Ci-C i) -alkyl, hydroxy or amino, wherein (Ci-C i) -alkyl having 1 to 3 substituents independently of one another selected from the group fluorine, trifluoromethyl, hydroxy, hydroxycarbonyl, ( C1-C4) - alkoxycarbonyl and amino may be substituted, is hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 6) -alkyl, (C 1 -C 4) -alkoxycarbonylamino, cyano, (C 3 -C 7) -cycloalkyl, difluoromethoxy, trifluoromethoxy, phenyl or a group of the formula -MR 13 , in which (C 1 -C 6 ) -alkyl having 1 to 3 substituents selected independently of one another from the group of fluorine, cyano, trifluoromethyl, (C 3 -C
- M is a bond or (C 1 -C 4) -alkanediyl
- R, R and R are each independently hydrogen
- R and R together with the atom (s) to which they are attached, form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle, in turn, is independently selected from the group consisting of 1 or 2 substituents Cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and di- ( Ci-C6) -alkylamino may be substituted, or R and R, together with the atom (s) to which they are attached, form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle, in turn, is independently selected from the group consisting of 1 or 2 substituents Cyano, trifluoromethyl, (C 1 -C 6) -al
- R 17 is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, or
- R 14 and R 17 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and di - (Ci-C6) -alkylamino, and wherein 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl in turn having 1 to 3 substituents independently selected from the group halogen, cyano, difluoromethyl, trifluoromethyl , (C 1 -C 6) -alkyl, (C 3 -C 4) -cycl
- R 7A and R 7B together with the carbon atom to which they are attached, a
- Form carbocycle or a 4- to 7-membered heterocycle wherein the 3- to 6-membered carbocycle and the 4- to 7-membered heterocycle having 1 or 2 substituents independently selected from the group fluorine and (Ci-C i) - R 8A is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or hydroxyl,
- R 8B is hydrogen, fluorine, (C 1 -C 4 ) -alkyl or trifluoromethyl, the ring Q is 8- or 9-membered heteroaryl,
- R 3 is -OR 4 or -NR 5 R 6 , wherein R 4 is hydrogen, (Ci-C 6 ) alkyl, (C 3 -C 7 ) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl or 5 - or 6-membered heteroaryl, wherein (Ci-C6) alkyl, (C3-Cv) cycloalkyl, 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl having 1 to 3 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 6) -alkyl, (C 3 -C 6) -cycloalkyl, difluoromethoxy, trifluoromethoxy,
- R 9 , R 10 and R 11 independently of one another each represent hydrogen, (C 1 -C 6) -alkyl or (C 3 -C 6) -cycloalkyl, where rin (Ci-C6) -Al ky 1 in turn with 1 or 2 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, hydroxy, (Ci-C6) alkoxy, difluoromethoxy, trifluoromethoxy, (Ci-C6) Alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino, di (C 1 -C 6) -alkylamino and 4 to 7-membered heterocyclyl, or together with the atom (s) to which they are each bonded, a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn with 1 or 2 substituents independently selected from the group fluorine, trifluoromethyl, (Ci-C6)
- R is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, and in which the abovementioned (C 1 -C 4 ) -alkyl, (C 1 -C 6 ) -alkyl, (C 3 -Cg) -Cycloalkyl, (C3-C7) -cycloalkyl and 4- to 7-membered heterocyclyl groups, unless stated otherwise, each independently with 1 to 3 substituents independently selected from among fluorine, difluoromethyl, trifluoromethyl, (C 1 -C 4) -alkyl, (C 3 -C 4) -cycloalkyl, hydroxy, difluoromethoxy, trifluoromethoxy, (C 1 -C 4) -alkoxy, hydroxycarbonyl, (C 1 -C 4) - Alkoxycarbonyl, amino, phenyl, 4- to 7-membered heterocyclyl and
- R 6 is (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl or 5- or 6-membered heteroaryl, in which (C 1 -C 6) -alkyl ( C 3 -C 4) -cycloalkyl, 4- to 7-membered heterocyclyl, phenyl and 5- or 6-membered heteroaryl having 1 to 3 substituents independently of one another selected from the group consisting of fluorine, difluoromethyl, trifluoromethyl,
- OR 10 , -NR 9 - (C O) -NR 10 R u , -NR 9 -SO 2 -R 10 , -S (O) q -R 12 , -S0 2 -NR 9 R 10 , phenyl, 4 - be substituted to 7-membered heterocyclyl and 5- or 6-membered heteroaryl, wherein p is the number 0 or 1, q is the number 0, 1 or 2,
- R 9 , R 10 and R 11 are each independently hydrogen
- R 9 and R 10 together with the atom (s) to which they are respectively attached, form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group fluorine, cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkyl - Amino and di- (Ci-C6) -alkylamino may be substituted, or
- R 10 and R 11 together with the atom (s) to which they are respectively attached form a 4- to 7-membered heterocycle, wherein the 4- to 7-membered heterocycle in turn is independently selected with 1 or 2 substituents from the group cyano, trifluoromethyl, (C 1 -C 6) -alkyl, hydroxy, oxo, (C 1 -C 6) -alkoxy, trifluoromethoxy, (C 1 -C 6) -alkoxycarbonyl, amino, mono- (C 1 -C 6) -alkylamino and di - (Ci-C6) -alkylamino may be substituted, in which
- R 12 is (C 1 -C 6 ) -alkyl or (C 3 -C 7 ) -cycloalkyl, and wherein phenyl, 4- to 7-membered heterocyclyl and 5- or 6-membered heteroaryl in turn are independently selected with 1 to substituents from the group halogen, cyano, difluoromethyl, trifluoromethyl, (C 1 -C 4 ) -alkyl, (C 3 -C 7 ) -cycloalkyl, hydroxy, oxo, difluoromethoxy, trifluoromethoxy and (Ci-C i) alkoxy be substituted can,
- a 4- to 7-membered heterocycle or a 5- or 6-membered heteroaryl in which the 4- to 7-membered heterocycle and the 5- or 6-membered heteroaryl with 1 to 3 substituents independently of one another selected from the group fluorine, cyano, difluoromethyl, trifluoromethyl, (C 1 -C 6 ) -alkyl, (C 3 -C 7 ) -cycloalkyl, hydroxy, oxo, (C 1 -C 6 ) -alkoxy, difluoro- methoxy, trifluoromethoxy, (C 1 -C 6) alkoxycarbonyl, (C 1 -C 6) alkylcarbonylamino, amino, mono (C 1 -C 6) -alkylamino, di (C 1 -C 6) -alkylamino and 4 to 7-membered Heterocyclyl can be substituted, and in which the above
- R 1 is fluorine, chlorine, cyano, difluoromethyl, trifluoromethyl, (Ci-C 4 ) -alkyl, (C 3 -C 7 ) -cycloalkyl or (Ci-C i) -alkoxy, n is a number 0, 1 or 2 stands,
- R 2 is trifluoromethyl, (C 1 -C 6) -alkyl, (C 3 -C 9) -cycloalkyl, phenyl or 5- or 6-membered heteroaryl, where (C 1 -C 6) -alkyl having a substituent selected from the group consisting of difluoromethyl and trifluoromethyl substituted (Ci-C6) alkyl may be substituted by 1 to 3 substituents fluorine, wherein (C3-Cg) cycloalkyl may be substituted with 1 or 2 substituents independently selected from the group fluorine, methyl and methoxy, wherein Phenyl having 1 to 3 substituents fluorine, wherein phenyl may be substituted with 1 or 2 substituents independently selected from the group of methyl and methoxy, and wherein 5- and 6-membered heteroaryl having 1 or 2 substituents independently selected from the group Fluorine, trifluoromethyl and methyl may be substituted, and their N-oxides
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where is the point of attachment to the carbonyl group, is the point of attachment to the pyrimidine ring, is a number 0 or 1, is hydrogen, fluorine, methyl, ethyl, hydroxy or amino, is hydrogen, fluorine, difluoromethyl, trifluoromethyl, (C C i) alkyl, methoxycarbonylamino, cyano, cyclopropyl, cyclobutyl, cyclopentyl, phenyl or a group of the formula -MR 13 , wherein (Ci-C i) -alkyl having 1 to 3 substituents independently selected from the group fluorine , Cyano, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, eth
- M is a bond or methylene
- R 14 and R 15 are each independently hydrogen, methyl,
- Ethyl iso -propyl, cyclopropyl, cyclobutyl, cyclopentyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl or pyridyl, wherein methyl, ethyl and iso -propyl are further independently 1 or 2 substituents selected from among fluorine, difluoromethyl, trifluoromethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, difluoromethoxy, trifluoromethoxy, methoxy, ethoxy, hydroxycarbonyl, Methoxycarbonyl, ethoxycarbonyl and amino may be substituted, and wherein oxadiazolonyl, oxadiazolothion
- a 1 , A 2 , A 3 and A 4 are each independently N, CH or CR 1 , with the proviso that at most two of the groups A 1 , A 2 , A 3 and A 4 are N, R 3 is -OR 4 or -NR 5 R 6 , where
- R 9 and R 10 are each independently hydrogen, methyl
- P is the number 0 or 1, independently of one another are each hydrogen, methyl, ethyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1, 1, 2,2,2-pentafluoroethyl, cyclopropyl, cyclobutyl or cyclopentyl, or
- R and R together with the atom (s) to which they are attached, form an azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl ring in which the azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl ring in turn with 1 or 2
- Substituents independently selected from the group of fluorine, trifluoromethyl, methyl, ethyl, hydroxy, oxo, methoxy, ethoxy, amino, methylamino, ethylamino, dimethylamino and diethylamino may be substituted, or
- R 2 is trifluoromethyl, 2,2,2-trifluoroethyl, 3,3,3-trifluoroprop-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl , Pyridyl, pyrimidinyl, pyrazinyl or pyridazinyl, wherein phenyl is substituted by 1 to 3 substituents fluorine, and wherein cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl and pyridazinyl may be substituted by 1 or 2 substituents fluorine, and their Salts, solvates and solvates of salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, where
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number 0
- R 7A is hydrogen, fluorine, methyl or hydroxy
- R 7B is hydrogen, fluorine, trifluoromethyl, methyl or 2,2,2-trifluoroethyl, or R 7A and R 7B together with the carbon atom to which they are attached, a
- R 1b is hydrogen or fluorine, is hydrogen or chlorine
- a 1 is N or CH, N is CH or CF, -NR 5 R 6 is where
- R ⁇ is hydrogen
- R 9 is hydrogen
- R 2 is 2-fluorophenyl, 2,3-difluorophenyl or 3-fluoropyrid-2-yl,
- # l represents the point of attachment to the carbonyl group
- # 2 represents the point of attachment to the pyrimidine ring
- R 7A is methyl
- R 7B is methyl
- R la is hydrogen or methyl
- R 1b is hydrogen or fluorine, is hydrogen or chlorine, is N or CH, is N, CH or CF, is -NR 5 Pv 6 , wherein
- R 5 is hydrogen, methyl or ethyl
- P is the number 0 or 1
- R 9 and R 10 are each independently hydrogen, methyl
- Ethyl trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, cyclopropyl or cyclobutyl, and wherein tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, phenyl, furanyl, pyrazolyl, imidazolyl, triazolyl and pyridyl in turn with 1 or 2 substituents independently selected from the group fluorine, " ⁇
- Substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, methyl, ethyl and oxo may be substituted, or
- 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, ethyl, 1-hydroxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo, methoxy, ethoxy, difluoromethoxy and trifluoromethoxy may be substituted
- R 2 is 3,3,3-trifluoroeth-1-yl, 2,2,3,3,3-pentafluoroprop-1-yl, phenyl or pyridyl, wherein phenyl is substituted with 1 to 3 fluorine substituents, and wherein pyridyl is with 1 substituent may be substituted fluorine, and their salts, solvates and solvates of the salts.
- L is a group # 1 -CR 7A R 7B - (CR 8A R 8B) m - # 2, which is the point of attachment to the carbonyl group, # is the point of attachment to the pyrimidine ring, m is a number 0, is hydrogen, fluorine, methyl, hydroxy, hydrogen, fluorine, methyl or trifluoromethyl, or
- attachment site is -CFh-R, where the point of attachment is pyrimidine
- R j is -OR 4 or -NR R, where
- R 9 and R 10 are each independently hydrogen or
- pyrazolyl having 1 or 2 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl, cyclopentyl is hydrogen, methyl or ethyl, (C 1 -C 6) -alkyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl , Pyridyl or pyrimidinyl, in which (C 1 -C 6) -alkyl having 1
- R 9 and R 10 are each independently hydrogen, methyl
- R 2 is 2-fluorophenyl, 2,3-difluorophenyl or 3-fluoropyrid-2-yl, and their salts, solvates and solvates of the salts.
- # 1 is the point of attachment to the carbonyl group
- # 2 is the point of attachment to the pyrimidine ring
- m is a number
- R 7A is methyl
- R 7B is methyl
- the ring Q represents a group of the formula
- R 9 and R 10 are each independently hydrogen or
- pyrazolyl having 1 or 2 substituents independently selected from the group fluorine, difluoromethyl, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl, methyl, cyclopropyl, cyclobutyl, cyclopentyl may be substituted, represents hydrogen, methyl or ethyl, is (C 1 -C 6) -alkyl, oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, phenyl, pyrazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, pyridyl or pyrimidinyl, in which C6) -alkyl having
- R 9 and R 10 are each independently hydrogen, methyl
- Azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, dihydropiperidinyl, piperazinyl, morpholinyl, pyrazolyl or imidazolyl ring in which the azetidinyl, pyrrolidinyl, imidazolidinyl, piperidinyl, dihydropiperdinyl, piperazinyl, morpholinyl, pyrazolyl and imidazolyl ring having 1 or 2 substituents selected independently of one another from the group of fluorine, cyano, difluoromethyl, trifluoromethyl, 2, 2,2-trifluoroethyl, 1,1,2,2-pentafluoroethyl, methyl, ethyl, 1-hydroxyethyl, cyclopropyl, cyclobutyl, cyclopentyl, hydroxy, oxo, methoxy, ethoxy, difluoromethoxy and
- R 2 is 2-fluorophenyl, 2,3-difluorophenyl or 3-fluoropyrid-2-yl, and their salts, solvates and solvates of the salts.
- compounds of the present invention according to formula (I) which show an activity on recombinant guanylate cyclase reporter cell lines according to the investigation under B-2 as minimally effective concentration (MEC) of ⁇ 3 ⁇ and an inhibition of human phosphodiesterase 5 (PDE5). according to the study under B-6 as IC50 ⁇ 100 nm, and their salts, solvates and solvates of the salts.
- MEC minimally effective concentration
- PDE5 human phosphodiesterase 5
- MEC minimally effective concentration
- PDE5 human phosphodiesterase 5
- the invention further provides a process for the preparation of the compounds of the formula (I) according to the invention which comprises reacting a compound of the formula (II)
- n, L, Q, R 1 and R 2 are each as defined above, in an inert solvent with isopentyl nitrite and a halogen equivalent in a compound of formula (III)
- n, L, Q, R 1 , R 2 and R 3 are each as defined above, and optionally the resulting compounds of formula (I) optionally with the appropriate (i) solvents and / or (ii) acids or bases are converted into their solvates, salts and / or solvates of the salts.
- the process step (II) -> (III) takes place with or without solvent.
- Suitable solvents are all organic solvents which are inert under the reaction conditions.
- Preferred solvent is dimethoxyethane.
- the reaction (II) -> (III) is generally carried out in a temperature range of + 20 ° C to + 100 ° C, preferably in the range of + 50 ° C to + 100 ° C, optionally in a microwave.
- the reaction can be carried out at normal, elevated or reduced pressure (for example in the range from 0.5 to 5 bar). Generally, one works at normal pressure.
- Suitable halogen sources in the reaction (II) -> ⁇ (III) are, for example, diiodomethane, a mixture of cesium iodide, iodine and copper (I) iodide or copper (II) bromide.
- n, L, Q, R 1 and R 2 are each as defined above, take place.
- the Mitsunobu reaction is carried out using triphenylphosphine, or tri-n-butylphosphine, 1, 2-bis (diphenylphosphino) ethane (DPPE), diphenyl (2-pyridyl) phosphine (Ph2P-Py), (p-dimethylaminophenyl) diphenylphosphine (DAP-DP), tris (4-dimethylaminophenyl) phosphine (tris-DAP) and a suitable suitable alkyl azo dicarboxylate, as well as diethyl azodicarboxylate (DEAD), diisopropyl azodicarboxylate (DIAD), di-tert-butyl azodicarboxylate, ⁇ , ⁇ , ⁇ ' ⁇ '-tetramethylazodicarboxamide (TMAD), 1,1'-azodicarbonyl-dipiperidine (ADDP) or 4,7-dimethyl-3
- triphenylphosphine and diisopropyl azodicarboxylate are used, or a suitable azodicarbonamide such as N, N, N ', N'-tetramethyldiazene-1,2-dicarboxamide.
- Inert solvents for the Mitsunobu reaction (IA) + (IV) - > (I) are, for example, ethers, such as tetrahydrofuran, diethyl ether, co-liquids, benzene, toluene, xylene, halogenated hydrocarbons, such as Dichloromethane, dichloroethane or other solvents such as acetonitrile, DMF or NMP. It is likewise possible to use mixtures of the solvents mentioned. Preferably, THF is used.
- the Mitsunobu reaction (III) + (IV) -> (I) is generally carried out in a temperature range from -78 ° C to + 180 ° C, preferably at 0 ° C to + 50 ° C, optionally in a microwave.
- the reactions may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar).
- the preparation of the compounds of formula (I) can also be prepared under alkylation conditions starting from a compound of formula (IA).
- an alkyl halide preferably alkyl iodide is reacted with base addition with (IA) in an inert solvent.
- Suitable bases for process step (I-A) -> (I) are the customary inorganic or organic bases. These include preferably alkali metal hydroxides such as lithium, sodium or potassium hydroxide, alkali metal or alkaline earth metal carbonates such as lithium, sodium, potassium, calcium or cesium carbonate, alkali alcoholates such as sodium or potassium, sodium or potassium or sodium or Potassium tert-butoxide, alkali metal hydrides such as sodium or potassium hydride or amides such as sodium amide, lithium or potassium bis (trimethylsilyl) amide or lithium diisopropylamide. Cesium carbonate is preferably used.
- alkali metal hydroxides such as lithium, sodium or potassium hydroxide
- alkali metal or alkaline earth metal carbonates such as lithium, sodium, potassium, calcium or cesium carbonate
- alkali alcoholates such as sodium or potassium, sodium or potassium or sodium or Potassium tert-butoxide
- alkali metal hydrides such as sodium or potassium hydride
- Inert solvents include, for example, ethers such as tetrahydrofuran, diethyl ether, hydrocarbons such as benzene, toluene, xylene, and other solvents such as DMF or NMP. It is likewise possible to use mixtures of the solvents mentioned. Preferably, DMF is used.
- the alkylation reaction is generally carried out in a temperature range from -78 ° C to + 180 ° C, preferably at 0 ° C to + 130 ° C, optionally in a microwave.
- the implementations can be performed at normal, elevated or reduced pressure (eg from 0.5 to 5 bar).
- the reaction (III) + (IV) -> (I) is generally carried out in a temperature range from + 20 ° C to + 200 ° C, preferably at + 150 ° C to + 200 ° C, preferably in a microwave.
- the reaction may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar).
- compounds of the formula (I-A) can also be prepared starting from compounds of the formula (V) by reaction with compounds of the formula (VIII)
- T 2 is (C 1 -C 4 ) -alkyl and R 'is (C 1 -C 4 ) -alkyl, are obtained as described, for example, in Foeldi, et al. , Chemical Reports, 1942, vol. 75, p. 760 described.
- Compounds of the formula (I-A) can, in a further alternative process, also be prepared starting from compounds of the formula (II) by reaction with nitrites in acids, if appropriate with the addition of water. Preference is given to sodium nitrite in a mixture of trifluoroacetic acid and water.
- the reaction (II)) -> (I-A) is generally carried out in a temperature range of -15 ° C to + 70 ° C, preferably at 0 ° C to + 40 ° C, with portionwise addition of the nitrite.
- the reaction may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar).
- the compounds of the formula (II) are known from the literature (see, for example, WO 2010/065275, WO 201/1 15804 and WO 201 1/149921) or can be prepared in analogy to processes known from the literature.
- the compounds of formula (II) can be prepared by reacting a compound of formula (V)
- T 1 is (C 1 -C 4 ) -alkyl, to give a compound of the formula (II)
- Inert solvents for process step (V) + (VI) - > (II) are, for example, alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol or tert-butanol, ethers such as diethyl ether, dioxane, dimethoxyethane, tetrahydrofuran , Glycol dimethyl ether or diethylene glycol dimethyl ether, hydrocarbons such as benzene, xylene, toluene, hexane, cyclohexane or petroleum fractions, or other solvents such as dimethylformamide (DMF), dimethyl sulfoxide (DMSO), NN-dimethylpropyleneurea (DMPU), N-methylpyrrolidone ( ⁇ ), pyridine , Acetonitrile,
- Suitable bases for process step (V) + (VI) -> (II) are alkali metal hydroxides such as lithium, sodium or potassium hydroxide, alkali metal carbonates such as lithium, sodium, potassium or cesium carbonate, alkali metal bicarbonates such as sodium or potassium bicarbonate , Alkali metal such as sodium or potassium methoxide, sodium or potassium or potassium tert-butoxide, or organic amines such as triethylamine, diisopropylethylamine, pyridine, l, 8-diazabicyclo [5.4.0] undec-7-en (DBU) or l , 5-diazabicyclo [4.3.0] non-5-ene (DBN). Preference is given to potassium tert-butoxide or sodium methoxide.
- alkali metal hydroxides such as lithium, sodium or potassium hydroxide
- alkali metal carbonates such as lithium, sodium, potassium or cesium carbonate
- alkali metal bicarbonates such as sodium or potassium bi
- the reaction (V) + (VI) -> (II) is generally carried out in a temperature range of + 20 ° C to + 150 ° C, preferably at + 75 ° C to + 100 ° C, optionally in a microwave.
- the reaction may be carried out at normal, elevated or reduced pressure (e.g., from 0.5 to 5 bar). Generally, one works at normal pressure.
- the preparation process described above can be illustrated by the following synthesis scheme (Scheme 3) by way of example:
- the compounds of the present invention act as potent stimulators of soluble guanylate cyclase and inhibitors of phosphodiesterase-5, have valuable pharmacological properties, and have an improved therapeutic profile, such as in vivo properties and / or their pharmacokinetic and / or metabolic profile. They are therefore suitable for the treatment and / or prophylaxis of diseases in humans and animals.
- the compounds of the invention cause vasorelaxation and inhibition of platelet aggregation and lead to a reduction in blood pressure and to an increase in coronary blood flow. These effects are mediated by direct stimulation of soluble guanylate cyclase and intracellular cGMP increase.
- the compounds of the invention potentiate the action of cGMP level enhancers such as EDHF (endothelium-derived relaxing factor), NO donors, protoporphyrin IX, arachidonic acid or phenylhydrazine derivatives.
- the compounds according to the invention are suitable for the treatment and / or prophylaxis of cardiovascular, pulmonary, thromboembolic and fibrotic disorders.
- the compounds according to the invention can therefore be used in medicaments for the treatment and / or prophylaxis of cardiovascular diseases such as hypertension, resistant hypertension, acute and chronic heart failure, coronary heart disease, stable and unstable angina pectoris, peripheral and cardiac vascular diseases, arrhythmias, atrial arrhythmias and the chambers as well as conduction disorders such as " ⁇
- atrio-ventricular blockades grade I-III (AB block I-III), supraventricular tachyarrhythmia, atrial fibrillation, atrial flutter, ventricular fibrillation, ventricular tachyarrhythmia, torsade de pointes tachycardia, atrial and ventricular extrasystoles, AV- junctional extrasystoles, sick sinus syndrome, syncope, AV nodal reentrant tachycardia, Wolff-Parkinson-White syndrome, acute coronary syndrome (ACS), autoimmune heart disease (pericarditis, endocarditis, valvolitis, aortitis, cardiomyopathy), shock such as cardiogenic shock, septic shock and anaphylactic shock, aneurysms, premature ventricular contraction (PVC), for the treatment and / or prophylaxis of thromboembolic disorders and ischemia such as myocardial ischemia, myocardial infarction, stroke, cardiac hypertrophy
- cardiac failure includes both acute and chronic manifestations of cardiac insufficiency, as well as more specific or related forms of disease such as acute decompensated heart failure, right heart failure, left heart failure, global insufficiency, ischemic cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, idiopathic cardiomyopathy, congenital heart defects.
- Heart failure in heart valve defects mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, tricuspid insufficiency, pulmonary valve stenosis, pulmonary valvular insufficiency, combined valvular heart failure, myocarditis, chronic myocarditis, acute myocarditis, viral myocarditis, diabetic heart failure, alcoholic cardiomyopathy, cardiac storage disorders, diastolic heart failure as well as systolic heart failure and acute phases de w worsening of heart failure.
- the compounds according to the invention may also be used for the treatment and / or prophylaxis of arteriosclerosis, lipid metabolism disorders, hypolipoproteinemias, dyslipidaemias, hypertriglyceridemias, hyperlipidemias, hypercholesterolemias, abetelipoproteinemia, "
- Sitosterolemia Sitosterolemia, xanthomatosis, Tangier disease, obesity (obesity), obesity and combined hyperlipidaemias and metabolic syndrome.
- the compounds of the invention may be used for the treatment and / or prophylaxis of primary and secondary Raynaud's phenomenon, microcirculatory disorders, claudication, peripheral and autonomic neuropathies, diabetic microangiopathies, diabetic retinopathy, diabetic ulcers on the extremities, gangrenous, CREST syndrome, erythematosis, onychomycosis , rheumatic diseases and to promote wound healing.
- the compounds according to the invention are suitable for the treatment of urological diseases such as, for example, benign prostate syndrome (BPS), benign prostatic hyperplasia (BPH), benign prostatic hyperplasia (BPE), bladder emptying disorder (BOO), lower urinary tract syndromes (LUTS, including Feiine's urological syndrome ( FUS)), diseases of the urogenital system including neurogenic overactive bladder (OAB) and (IC), incontinence (UI) such as mixed, urge, stress, or overflow incontinence (MUI, UUI, SUI, OUI), Pelvic pain, benign and malignant diseases of the organs of the male and female urogenital system.
- BPS benign prostate syndrome
- BPH benign prostatic hyperplasia
- BPE benign prostatic hyperplasia
- BOO bladder emptying disorder
- LUTS lower urinary tract syndromes
- FUS Feiine's urological syndrome
- diseases of the urogenital system including neurogenic overactive bladder (OAB) and (IC), incontinence
- kidney diseases in particular of acute and chronic renal insufficiency, as well as of acute and chronic renal failure.
- renal insufficiency includes both acute and chronic manifestations of renal insufficiency, as well as underlying or related renal diseases such as renal hypoperfusion, intradialytic hypotension, obstructive uropathy, glomerulopathies, glomerulonephritis, acute glomerulonephritis, glomerulosclerosis, tubulointerstitial disorders, nephropathic disorders such as primary and congenital kidney disease, nephritis, renal immunological diseases such as renal transplant rejection, immune complex-induced renal disease, toxicant-induced nephropathy, contrast agent-induced nephropathy, diabetic and nondiabetic nephropathy, pyelonephritis, renal cysts, nephrosclerosis, hypertensive
- the present invention also encompasses the use of the compounds according to the invention for the treatment and / or prophylaxis of secondary effects of renal insufficiency, such as, for example, pulmonary edema, adrenal insufficiency, uremia, anemia, Electrolyte imbalances (eg, hyperkalemia, hyponatremia) and disorders in bone and carbohydrate metabolism.
- renal insufficiency such as, for example, pulmonary edema, adrenal insufficiency, uremia, anemia, Electrolyte imbalances (eg, hyperkalemia, hyponatremia) and disorders in bone and carbohydrate metabolism.
- the compounds according to the invention are also suitable for the treatment and / or prophylaxis of asthmatic diseases, pulmonary arterial hypertension (PAH) and other forms of pulmonary hypertension (PH), including left heart disease, HIV, sickle cell anemia, thromboembolism (CTEPH), sarcoidosis, COPD or Pulmonary fibrosis-associated pulmonary hypertension, chronic obstructive pulmonary disease (COPD), acute respiratory syndrome (ARDS), acute lung injury (ALI), alpha-1-antitrypsin deficiency (AATD), pulmonary fibrosis, pulmonary emphysema (eg, cigarette smoke induced pulmonary emphysema) and cystic fibrosis (CF).
- PAH pulmonary arterial hypertension
- PH pulmonary hypertension
- COPD chronic obstructive pulmonary disease
- ARDS acute respiratory syndrome
- ALI acute lung injury
- AATD alpha-1-antitrypsin deficiency
- CF cystic
- the compounds described in the present invention are also agents for controlling diseases in the central nervous system, which are characterized by disorders of the NO / cGMP system.
- they are suitable for improving the perception, concentration, learning performance or memory performance after cognitive disorders, such as those found in situations / diseases / syndromes such as mild cognitive impairment, age-associated learning and memory disorders, age-associated memory loss, vascular dementia, cranial Brain trauma, stroke, post-stroke dementia, post-traumatic traumatic brain injury, generalized concentration disorder, difficulty concentrating in children with learning and memory problems, Alzheimer's disease, dementia Lewy bodies, dementia with degeneration of the frontal lobes including Pick's syndrome, Parkinson's disease, progressive nuclear palsy, dementia with corticobasal degeneration, amyolateral sclerosis (ALS), Huntington's disease, demyelinization, multiple sclerosis, thalamic degeneration, Creutzfeld-Jacob -the enz, HIV dementia, schizophrenia with dementia or Korsakoff's psychosis. They are also suitable for the
- the compounds according to the invention are also suitable for regulating cerebral blood flow and are effective agents for combating migraine. They are also suitable for the prophylaxis and control of the consequences of cerebral infarct events (Apoplexia cerebri) such as stroke, cerebral ischaemias and craniocerebral trauma , Likewise, the compounds of the invention can be used to combat pain and tinnitus. "Apoplexia cerebri) such as stroke, cerebral ischaemias and craniocerebral trauma , Likewise, the compounds of the invention can be used to combat pain and tinnitus.
- the compounds of the invention have anti-inflammatory action and can therefore be used as anti-inflammatory agents for the treatment and / or prophylaxis of sepsis (SIRS), multiple organ failure (MODS, MOF), inflammatory diseases of the kidney, chronic inflammatory bowel disease (IBD, Crohn's Disease, UC), pancreatitis , Peritonitis, rheumatoid diseases, inflammatory skin diseases and inflammatory ocular diseases.
- SIRS sepsis
- MODS multiple organ failure
- IBD chronic inflammatory bowel disease
- UC chronic inflammatory bowel disease
- pancreatitis atitis
- Peritonitis rheumatoid diseases
- inflammatory skin diseases and inflammatory ocular diseases.
- the compounds of the invention can also be used for the treatment and / or prophylaxis of autoimmune diseases.
- the compounds according to the invention are suitable for the treatment and / or prophylaxis of fibrotic disorders of the internal organs such as, for example, the lung, the heart, the kidney, the bone marrow and in particular the liver, as well as dermatological fibroses and fibrotic disorders of the eye.
- fibrotic disorders includes in particular the following terms: liver fibrosis, cirrhosis of the liver, pulmonary fibrosis, endomyocardial fibrosis, nephropathy, glomerulonephritis, interstitial renal fibrosis, fibrotic damage as a result of diabetes, bone marrow fibrosis and similar fibrotic disorders, scleroderma, morphea, keloids, hypertrophic scarring (also after surgical procedures), nevi, diabetic retinopathy, proliferative vitroretinopathy and connective tissue disorders (eg sarcoidosis).
- the compounds of the invention are useful for controlling postoperative scarring, e.g. as a result of glaucoma surgery.
- the compounds according to the invention can likewise be used cosmetically for aging and keratinizing skin.
- the compounds according to the invention are suitable for the treatment and / or prophylaxis of hepatitis, neoplasm, osteoporosis, glaucoma and gastroparesis.
- Another object of the present invention is the use of the compounds of the invention for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
- the present invention further relates to the use of the compounds according to the invention for the treatment and / or prophylaxis of cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency, thromboembolic disorders, fibrotic disorders and atherosclerosis.
- the present invention furthermore relates to the compounds according to the invention for use in a method for the treatment and / or prophylaxis of cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular diseases, renal insufficiency, thromboembolic disorders, fibrotic disorders and arteriosclerosis.
- Another object of the present invention is the use of the compounds of the invention for the manufacture of a medicament for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases.
- the present invention further relates to the use of the compounds according to the invention for the production of a medicament for the treatment and / or prophylaxis of cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular disorders, renal insufficiency, thromboembolic disorders, fibrotic disorders and arteriosclerosis.
- Another object of the present invention is a method for the treatment and / or prophylaxis of diseases, in particular the aforementioned diseases, using an effective amount of at least one of the compounds of the invention.
- the present invention further provides a method for the treatment and / or prophylaxis of cardiac insufficiency, angina pectoris, hypertension, pulmonary hypertension, ischaemias, vascular diseases, renal insufficiency, thromboembolic disorders, fibrotic diseases and atherosclerosis, using an effective amount of at least one of the compounds according to the invention ,
- the compounds of the invention may be used alone or as needed in combination with other agents.
- Another object of the present invention are pharmaceutical compositions containing at least one of the compounds of the invention and one or more other active ingredients, in particular for the treatment and / or prophylaxis of the aforementioned diseases.
- suitable combination active ingredients may be mentioned by way of example and preferably:
- organic nitrates and NO donors such as sodium nitroprusside, nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, molsidomine or SIN-1, and inhaled NO;
- cGMP cyclic guanosine monophosphate
- PDE phosphodiesterases
- Inhibitors such as sildenafil, vardenafil and tadalafil;
- Antithrombotic agents by way of example and preferably from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances;
- Antihypertensive agents by way of example and preferably from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blockers, beta-receptor blockers, mineralocorticides co-receptor antagonists and diuretics; and or
- Lipid metabolism-altering agents by way of example and preferably from the group of thyroid receptor agonists, cholesterol synthesis inhibitors such as by way of example and preferably HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR inhibitors alpha, PPAR gamma and / or PPAR delta agonists,
- cholesterol synthesis inhibitors such as by way of example and preferably HMG-CoA reductase or squalene synthesis inhibitors, ACAT inhibitors, CETP inhibitors, MTP inhibitors, PPAR inhibitors alpha, PPAR gamma and / or PPAR delta agonists,
- Cholesterol absorption inhibitors lipase inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, and lipoprotein (a) antagonists.
- Antithrombotic agents are preferably understood as meaning compounds from the group of platelet aggregation inhibitors, anticoagulants or profibrinolytic substances.
- the compounds according to the invention are administered in combination with a platelet aggregation inhibitor, such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
- a platelet aggregation inhibitor such as, by way of example and by way of preference, aspirin, clopidogrel, ticlopidine or dipyridamole.
- the compounds according to the invention are administered in combination with a thrombin inhibitor, such as, by way of example and by way of preference, ximelagatran, dabigatran, melagatran, bivalirudin or Clexane.
- a thrombin inhibitor such as, by way of example and by way of preference, ximelagatran, dabigatran, melagatran, bivalirudin or Clexane.
- the compounds according to the invention are administered in combination with a GPIIb / IIIa antagonist, such as, by way of example and by way of preference, tirofiban or abciximab.
- a GPIIb / IIIa antagonist such as, by way of example and by way of preference, tirofiban or abciximab.
- the compounds according to the invention are used in combination with a factor Xa inhibitor, such as by way of example and preferably rivaroxaban (BAY 59-7939), DU-176b, apixaban, otamixaban, fidexaban, razaxaban, fondaparinux, idraparinux, PMD 31 12, YM-150, KFA-1982, EMD-503982, MCM-17, MLN-1021, DX 9065a, DPC 906, JTV 803, SSR-126512 or SSR-128428.
- rivaroxaban BAY 59-7939
- the compounds according to the invention are administered in combination with heparin or a low molecular weight (LMW) heparin derivative.
- LMW low molecular weight
- the compounds according to the invention are administered in combination with a vitamin K antagonist, such as by way of example and preferably coumarin.
- antihypertensive agents are preferably compounds from the group of calcium antagonists, angiotensin AII antagonists, ACE inhibitors, endothelin antagonists, renin inhibitors, alpha-receptor blocker, beta-receptor blocker, mineralocorticoid receptor - understood antagonists and diuretics.
- the compounds according to the invention are administered in combination with a calcium antagonist, such as by way of example and preferably nifedipine, amlodipine, verapamil or diltiazem.
- a calcium antagonist such as by way of example and preferably nifedipine, amlodipine, verapamil or diltiazem.
- the compounds according to the invention are administered in combination with an alpha-1-receptor blocker, such as by way of example and preferably prazosin.
- the compounds according to the invention are used in combination with a beta-receptor blocker such as, by way of example and by way of preference, propranolol, atenolol, timolol, pindolol, alprenolol, oxprenolol, penbutolol, bupranolol, metipropanol, nadolol, mepindolol, Caroteneol, sotalol, metoprolol, betaxolol, celiprolol, bisoprolol, carteolol, esmolol, labetalol, carvedilol, adaprolol, landiolol, nebivolol, epanolol or bucinolol.
- a beta-receptor blocker such as, by way of example and by way of preference, propranolol, atenolol,
- the compounds according to the invention are administered in combination with an angiotensin AII antagonist, such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan.
- an angiotensin AII antagonist such as by way of example and preferably losartan, candesartan, valsartan, telmisartan or embursatan.
- the compounds according to the invention are administered in combination with an ACE inhibitor such as, by way of example and by way of preference, enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
- an ACE inhibitor such as, by way of example and by way of preference, enalapril, captopril, lisinopril, ramipril, delapril, fosinopril, quinopril, perindopril or trandopril.
- the compounds according to the invention are administered in combination with an endothelin antagonist such as, by way of example and by way of preference, bosentan, darusentan, ambrisentan or sitaxsentan.
- an endothelin antagonist such as, by way of example and by way of preference, bosentan, darusentan, ambrisentan or sitaxsentan.
- the compounds according to the invention are administered in combination with a renin inhibitor, such as by way of example and preferably aliskiren, SPP-600 or SPP-800.
- the compounds of the invention are administered in combination with a mineralocorticoid receptor antagonist, such as by way of example and preferably spironolactone or eplerenone.
- a mineralocorticoid receptor antagonist such as by way of example and preferably spironolactone or eplerenone.
- the compounds of the present invention are used in combination with a loop diuretic such as furosemide, torasemide, bumetanide and piretanide with potassium sparing diuretics such as amiloride and triamterene with aldosterone antagonists such as spironolactone, potassium canrenoate and eplerenone and thiazide diuretics such as Hydrochlorothiazide, chlorthalidone, xipamide, and indapamide.
- a loop diuretic such as furosemide, torasemide, bumetanide and piretanide
- potassium sparing diuretics such as amiloride and triamterene with aldosterone antagonists such as spironolactone, potassium canrenoate and eplerenone and thiazide diuretics
- Hydrochlorothiazide chlorthalidone
- xipamide xipamide
- indapamide indapamide
- lipid metabolizing agents are preferably compounds from the group of CETP inhibitors, thyroid receptor agonists, cholesterol synthesis inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors, the ACAT inhibitors, MTP inhibitors, PPAR alpha- , PPAR gamma and / or PPAR delta agonists, cholesterol absorption inhibitors, polymeric bile acid adsorbers, bile acid reabsorption inhibitors, lipase inhibitors and the lipoprotein (a) antagonists understood.
- CETP inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
- ACAT inhibitors such as HMG-CoA reductase or squalene synthesis inhibitors
- MTP inhibitors MTP inhibitors
- PPAR alpha- , PPAR gamma and / or PPAR delta agonists cholesterol absorption inhibitors
- polymeric bile acid adsorbers bile acid rea
- the compounds according to the invention are administered in combination with a CETP inhibitor, such as, for example and preferably, dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).
- a CETP inhibitor such as, for example and preferably, dalcetrapib, BAY 60-5521, anacetrapib or CETP vaccine (CETi-1).
- the compounds according to the invention are administered in combination with a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214) ,
- a thyroid receptor agonist such as, by way of example and by way of preference, D-thyroxine, 3,5,3'-triiodothyronine (T3), CGS 23425 or axitirome (CGS 26214) ,
- the compounds according to the invention are administered in combination with an HMG-CoA reductase inhibitor from the class of statins, such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
- statins such as by way of example and preferably lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin or pitavastatin.
- the compounds according to the invention are administered in combination with a squalene synthesis inhibitor, such as by way of example and preferably BMS-188494 or TAK-475.
- a squalene synthesis inhibitor such as by way of example and preferably BMS-188494 or TAK-475.
- the compounds according to the invention are administered in combination with an ACAT inhibitor, such as by way of example and preferably avasimibe, melinamide, pactimibe, eflucimibe or SMP-797.
- an MTP inhibitor such as, for example and preferably, implitapide, BMS-201038, R-103757 or JTT-130.
- the compounds according to the invention are administered in combination with a PPAR-gamma agonist, such as, by way of example and by way of preference, pioglitazone or rosiglitazone.
- a PPAR-gamma agonist such as, by way of example and by way of preference, pioglitazone or rosiglitazone.
- the compounds according to the invention are administered in combination with a PPAR delta agonist, such as by way of example and preferably GW 501516 or BAY 68-5042.
- a PPAR delta agonist such as by way of example and preferably GW 501516 or BAY 68-5042.
- the compounds according to the invention are administered in combination with a cholesterol absorption inhibitor, such as by way of example and preferably ezetimibe, tiqueside or pamaqueside.
- the compounds according to the invention are administered in combination with a lipase inhibitor, such as, for example and preferably, orlistat.
- a lipase inhibitor such as, for example and preferably, orlistat.
- the compounds of the invention are administered in combination with a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
- a polymeric bile acid adsorbent such as, by way of example and by way of preference, cholestyramine, colestipol, colesolvam, cholesta gel or colestimide.
- the compounds of the invention are administered in combination with a lipoprotein (a) antagonist such as, by way of example and by way of preference, gemcabene calcium (CI-1027) or nicotinic acid.
- a lipoprotein (a) antagonist such as, by way of example and by way of preference, gemcabene calcium (CI-1027) or nicotinic acid.
- compositions containing at least one compound of the invention are pharmaceutical compositions containing at least one compound of the invention, usually together with one or more inert, non-toxic, pharmaceutically suitable excipients, and their use for the purposes mentioned above.
- the compounds according to the invention can act systemically and / or locally. For this purpose, they can be administered in a suitable manner, such as, for example, orally, parenterally, pulmonary, , ""
- the compounds of the invention can be administered in suitable administration forms.
- the compounds of the invention rapidly and / or modified donating application forms containing the compounds of the invention in crystalline and / or amorphized and / or dissolved form, such.
- Tablets uncoated or coated tablets, for example with enteric or delayed-release or insoluble coatings which control the release of the compound of the invention
- tablets or films / wafers rapidly breaking down in the oral cavity, films / lyophilisates, capsules (for example Hart - or soft gelatin capsules), dragees, granules, pellets, powders, emulsions, suspensions, aerosols or solutions.
- Parenteral administration can be accomplished by bypassing a resorption step (e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar) or by resorting to absorption (e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally).
- a resorption step e.g., intravenously, intraarterially, intracardially, intraspinal, or intralumbar
- absorption e.g., intramuscularly, subcutaneously, intracutaneously, percutaneously, or intraperitoneally.
- parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates or sterile powders.
- Inhalation medicines including powder inhalers, nebulizers
- nasal drops solutions or sprays
- lingual, sublingual or buccal tablets films / wafers or capsules
- suppositories ear or eye preparations
- vaginal capsules aqueous suspensions (lotions, shake mixtures ), lipophilic suspensions, ointments, creams, transdermal therapeutic systems (eg patches), milk, pastes, foams, powdered powders, implants or stents.
- Preference is given to oral or parenteral administration, in particular oral administration.
- the compounds of the invention can be converted into the mentioned application forms. This can be done in a conventional manner by mixing with inert, non-toxic, pharmaceutically suitable excipients.
- excipients include excipients (for example microcrystalline cellulose, lactose, mannitol), solvents (for example liquid polyethylene glycols), emulsifiers and dispersants or wetting agents (for example sodium dodecyl sulfate, polyoxysorbitanoleate), binders (for example polyvinylpyrrolidone), synthetic and natural polymers (For example, albumin), stabilizers (eg, antioxidants such as ascorbic acid), dyes (eg, inorganic pigments such as iron oxides) and flavor and / or odoriferous.
- excipients for example microcrystalline cellulose, lactose, mannitol
- solvents for example liquid polyethylene glycols
- emulsifiers and dispersants or wetting agents for example sodium dodecyl
- the dosage is about 0.001 to 2 mg / kg, preferably about 0.001 to 1 mg / kg of body weight.
- Device Type MS Waters ZQ; Device type HPLC: Agilent 1 100 Series; UV DAD; Column: Thermo Hypersil GOLD 3 ⁇ 20 mm x 4 mm; Eluent A: 1 l of water + 0.5 ml of 50% formic acid, eluent B: 1 l of acetonitrile + 0.5 ml of 50% formic acid; Gradient: 0.0 min 100% A -> 3.0 min 10% A-> 4.0 min 10% A, oven: 55 ° C; Flow 2ml / min; UV detection: 210 nm.
- the diazonium salt thus prepared was added in portions to a 0 ° C cold solution of 12.81 g (85.45 mmol) of sodium iodide in acetone (329 ml) and the mixture stirred for 30 min at RT.
- the reaction mixture was added to ice water (1.8 L) and extracted twice with ethyl acetate (487 mL each).
- the combined organic phases were washed with saturated aqueous sodium chloride solution (244 ml), dried, ⁇
- reaction mixture was concentrated to dryness and the residue was taken up in water (100 ml) and ethyl acetate (100 ml) and adjusted to pH 10 with 2N sodium hydroxide solution. It was stirred vigorously for about 1 h at RT. The resulting suspension was filtered off with suction and washed with ethyl acetate (100 ml), water (100 ml) and again ethyl acetate (100 ml). The residue is dried over phosphorus pentoxide in a high vacuum.
- Example 1A 5,887 g (19,256 mmol) of Example 1A were initially charged in tert-butanol (50 ml) and treated with 2,593 g (23.107 mmol) of potassium tert-butoxide. Subsequently, 3.2 g (19.256 mmol) of Example 12A in tert-butanol (25 ml) were added dropwise and the mixture was heated to reflux overnight. The next day, another 0.64 g (3.851 mmol) of Example 12A was added and heated to reflux for a further day. After cooling, a precipitate was filtered off, which was washed with diethyl ether. It was then slurried in water and filtered once more and washed with diethyl ether. After drying under high vacuum, it was possible to obtain 6.65 g of the title compound (85% of theory).
- Example 11A In analogy to the preparation of Example 13A, 4.18 g (12.035 mmol) of Example 11A were reacted with 2.20 g (13.239 mmol) of Example 12A. There were 3.72 g of the title compound (73% d.
- Example 73A may be used instead of Example 11A for preparation.
- Example 15A 2- [1- (2-Fluorobenzyl) -1H-pyrazolo [3,4-b] pyridin-3-yl] -4-iodo-5,5-dimethyl-5,7-dihydro-6H-pyrrolo [ 2,3-d] pyrimidin-6-one
- Example 13A 5.00 g (12.394 mmol) of Example 13A were initially charged in iso-pentyl nitrite (35.87 ml) and diiodomethane (1.16 mol, 93.71 ml) and heated to 85 ° C. for 12 h. After cooling, it was filtered off from solids, the filtrate was concentrated and the residue was subsequently purified by chromatography on silica gel (mobile phase: first cyclohexane-dichloromethane gradient, then dichloromethane-methanol gradient). There were obtained 5.50 g of the title compound (67% of theory).
- Example 14A 3,325 g (7,890 mmol) of Example 14A were reacted in analogy to Example 15A. This gave 3.65 g of the title compound (87% of theory, about 61% purity according to LC / MS).
- Example 14A was stirred in dioxane (239 ml) with 91.26 g (340.75 mmol) of diiodomethane and 39.91 g (340.75 mmol) of isopentyl nitrite for 2 h at 85 ° C. _
- Example 20A 2,040 g (4,830 mmol) of Example 20A were initially charged in iso-pentylnitrite (14 ml) and diiodomethane (37 ml) and heated to 85 ° C. for 1 h. After cooling, a solid was filtered off, which was washed with a little acetonitrile. Subsequently, the solid was dried overnight under high vacuum. 1.83 g of the title compound were obtained (39% of theory, 55% purity). The crude compound was used without further purification in the next steps.
- Example 23A 12225 g (46,482 mmol) of 5-fluoro-3-iodo-1H-pyrazolo [3,4-b] pyridine were reacted with Example 23A in analogy to the procedure of Example 7A. There were obtained 1.34 g (65% of theory) of the title compound.
- Example 24A 11,340 g (30,474 mmol) of Example 24A were reacted in analogy to the procedure under Example 10A, variant A. There were obtained 6.31 g (76% of theory) of the title compound.
- Example 25A 6,310 g (23,264 mmol) of Example 25A were reacted in analogy to the procedure under Beisp. 6.12 g (75% of theory) of the title compound were obtained.
- Example 26A 3,050 g (8,756 mmol) of Example 26A were reacted in analogy to the procedure under Example 13A. Purification by preparative chromatography on silica gel (dichloromethane: methanol gradient). There were obtained 528 mg of the title compound (14% of Th,).
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
Claims
Priority Applications (17)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014527659A JP6054967B2 (ja) | 2011-09-02 | 2012-08-30 | 置換アネレート化ピリミジンおよびその使用 |
KR1020147008313A KR20140068112A (ko) | 2011-09-02 | 2012-08-30 | 치환된 융합 피리미딘 및 그의 용도 |
CN201280053847.5A CN104039784B (zh) | 2011-09-02 | 2012-08-30 | 取代的增环嘧啶及其用途 |
AP2014007541A AP2014007541A0 (en) | 2011-09-02 | 2012-08-30 | Substituted annellated pyrimidine and the use thereof |
EP12766292.2A EP2751106B1 (de) | 2011-09-02 | 2012-08-30 | Substituierte annellierte pyrimidine und ihre verwendung |
NZ621396A NZ621396B2 (en) | 2011-09-02 | 2012-08-30 | Substituted annellated pyrimidine and the use thereof |
MX2014002075A MX348470B (es) | 2011-09-02 | 2012-08-30 | Pirimidinas anilladas sustituidas y uso de las mismas. |
AU2012300844A AU2012300844B2 (en) | 2011-09-02 | 2012-08-30 | Substituted annellated pyrimidine and the use thereof |
BR112014005110A BR112014005110A2 (pt) | 2011-09-02 | 2012-08-30 | pirimidinas aneladas substituídas e utilização das mesmas |
CA 2847075 CA2847075A1 (en) | 2011-09-02 | 2012-08-30 | Substituted annellated pyrimidine and the use thereof |
SG11201400083VA SG11201400083VA (en) | 2011-09-02 | 2012-08-30 | Substituted annellated pyrimidine and the use thereof |
EA201490546A EA026701B1 (ru) | 2011-09-02 | 2012-08-30 | Замещенные аннелированные пиримидины, способ их получения, их применение и лекарственное средство для лечения и/или профилактики заболеваний |
MA36787A MA35365B1 (fr) | 2011-09-02 | 2014-02-28 | Pyrimidines annelées substituées et leur utilisation |
TNP2014000085A TN2014000085A1 (en) | 2012-01-11 | 2014-02-28 | Substituted annellated pyrimidine and the use thereof |
IL231244A IL231244A (en) | 2011-09-02 | 2014-03-02 | Conjugated pyrimidine analyzed and used |
CUP2014000025A CU20140025A7 (es) | 2011-09-02 | 2014-03-03 | Pirimidinas anilladas sustituidas |
HK14112217.6A HK1198698A1 (en) | 2011-09-02 | 2014-12-04 | Substituted annellated pyrimidine and the use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011082041.8 | 2011-09-02 | ||
DE201110082041 DE102011082041A1 (de) | 2011-09-02 | 2011-09-02 | Substituierte annellierte Pyrimidine und ihre Verwendung |
DE201210200351 DE102012200351A1 (de) | 2012-01-11 | 2012-01-11 | Substituierte annellierte Pyrimidine und ihre Verwendung |
DE102012200351.7 | 2012-01-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013030288A1 true WO2013030288A1 (de) | 2013-03-07 |
Family
ID=47755368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/066876 WO2013030288A1 (de) | 2011-09-02 | 2012-08-30 | Substituierte annellierte pyrimidine und ihre verwendung |
Country Status (27)
Country | Link |
---|---|
US (2) | US8859569B2 (de) |
EP (1) | EP2751106B1 (de) |
JP (1) | JP6054967B2 (de) |
KR (1) | KR20140068112A (de) |
CN (1) | CN104039784B (de) |
AP (1) | AP2014007541A0 (de) |
AR (1) | AR087769A1 (de) |
AU (1) | AU2012300844B2 (de) |
BR (1) | BR112014005110A2 (de) |
CA (1) | CA2847075A1 (de) |
CL (1) | CL2014000504A1 (de) |
CO (1) | CO6950471A2 (de) |
CR (1) | CR20140096A (de) |
CU (1) | CU20140025A7 (de) |
DO (1) | DOP2014000043A (de) |
EA (1) | EA026701B1 (de) |
EC (1) | ECSP14013224A (de) |
GT (1) | GT201400033A (de) |
HK (1) | HK1198698A1 (de) |
IL (1) | IL231244A (de) |
MA (1) | MA35365B1 (de) |
MX (1) | MX348470B (de) |
PE (1) | PE20141582A1 (de) |
SG (1) | SG11201400083VA (de) |
TW (1) | TWI565708B (de) |
UY (1) | UY34306A (de) |
WO (1) | WO2013030288A1 (de) |
Cited By (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013131923A1 (de) * | 2012-03-06 | 2013-09-12 | Bayer Intellectual Property Gmbh | Substituierte azabicyclen und ihre verwendung |
WO2014084312A1 (ja) | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
WO2014131741A1 (de) | 2013-03-01 | 2014-09-04 | Bayer Pharma Aktiengesellschaft | Benzyl-substituierte pyrazolopyridine und ihre verwendung |
WO2014131760A1 (de) | 2013-03-01 | 2014-09-04 | Bayer Pharma Aktiengesellschaft | Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung |
US20140309425A1 (en) * | 2011-12-12 | 2014-10-16 | Pharmablock (Nanjing) R&D Co., Ltd. | Method for synthesizing 1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine-3-formamidine hydrochloride |
WO2015088885A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2015089182A1 (en) | 2013-12-11 | 2015-06-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
WO2015124544A1 (de) * | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine |
WO2016030354A1 (de) | 2014-08-29 | 2016-03-03 | Bayer Pharma Aktiengesellschaft | Amino-substituierte annellierte pyrimidine und ihre verwendung |
WO2016030362A1 (de) | 2014-08-29 | 2016-03-03 | Bayer Pharma Aktiengesellschaft | Substituierte annellierte pyrimidine und ihre verwendung |
WO2016044446A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2016073889A1 (en) * | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
WO2016110821A1 (en) | 2015-01-08 | 2016-07-14 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
JP2016523944A (ja) * | 2013-07-10 | 2016-08-12 | バイエル・ファルマ・アクティエンゲゼルシャフト | ベンジル−1H−ピラゾロ[3,4−b]ピリジンおよびその使用 |
WO2016177660A1 (en) | 2015-05-06 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
US9637550B2 (en) | 2008-12-18 | 2017-05-02 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
US9636399B2 (en) | 2007-11-21 | 2017-05-02 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
WO2017106175A2 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
EP3079700A4 (de) * | 2013-12-11 | 2017-07-19 | Merck Sharp & Dohme Corp. | Lösliche guanylat-cyclase-aktivatoren |
US9732089B2 (en) | 2014-11-06 | 2017-08-15 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
US9783614B2 (en) | 2012-05-10 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof |
US9840510B1 (en) | 2016-04-06 | 2017-12-12 | Lysosomal Therapeutics Inc. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US9868742B2 (en) | 2016-05-05 | 2018-01-16 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders |
US9920061B2 (en) | 2016-04-06 | 2018-03-20 | Lysosomal Therapeutics Inc. | Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
KR20180095904A (ko) * | 2015-12-22 | 2018-08-28 | 머크 샤프 앤드 돔 코포레이션 | 심혈관 질환을 치료하기 위한 cGMP 조정제로서의 4-아미노-2-(1H-피라졸로[3,4-B]피리딘-3-일)-6-옥소-6,7-디히드로-5H-피롤로[2,3-D]피리딘 유도체 및 각각의 (1H-인다졸-3-일) 유도체 |
US10292970B2 (en) | 2014-12-02 | 2019-05-21 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use |
US10364229B2 (en) | 2011-11-25 | 2019-07-30 | Adverio Pharma Gmbh | Crystalline substituted 5-fluoro-1H-pyrazolopyridines and process for preparing |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
WO2020014504A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
WO2020165010A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
US10751341B2 (en) | 2014-11-06 | 2020-08-25 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
US11767337B2 (en) | 2020-02-18 | 2023-09-26 | Gilead Sciences, Inc. | Antiviral compounds |
WO2024038398A1 (en) * | 2022-08-18 | 2024-02-22 | Torrent Pharmaceuticals Limited | Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
EP2708539A1 (de) | 2010-07-09 | 2014-03-19 | Bayer Intellectual Property GmbH | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
CN103619845B (zh) | 2011-04-21 | 2016-08-17 | 拜耳知识产权有限责任公司 | 氟烷基取代的吡唑并吡啶及其用途 |
DE102012200360A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte Triazine und ihre Verwendung |
DE102012200352A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte, annellierte Imidazole und Pyrazole und ihre Verwendung |
DE102012200349A1 (de) | 2012-01-11 | 2013-07-11 | Bayer Intellectual Property Gmbh | Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung |
MX2015010725A (es) | 2013-02-21 | 2016-05-31 | Adverio Pharma Gmbh | Formas de metil {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato. |
WO2015187470A1 (en) | 2014-06-04 | 2015-12-10 | Merck Sharp & Dohme Corp. | Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators |
TW201625635A (zh) | 2014-11-21 | 2016-07-16 | 默沙東藥廠 | 作為可溶性鳥苷酸環化酶活化劑之三唑并吡基衍生物 |
WO2016149218A1 (en) * | 2015-03-13 | 2016-09-22 | Indiana University Research And Technology Corporation | TARGETING cGMP-RELATED PHOSPHODIESTERASES TO REDUCE CYST FORMATION IN CYSTIC KIDNEY DISEASE, AND RELATED MATERIALS AND METHODS |
US10245264B2 (en) | 2015-05-27 | 2019-04-02 | Merck Sharp & Dohme Corp. | Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators |
US10213429B2 (en) | 2015-05-28 | 2019-02-26 | Merck Sharp & Dohme Corp. | Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators |
WO2017197555A1 (en) | 2016-05-16 | 2017-11-23 | Merck Sharp & Dohme Corp. | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators |
WO2017200857A1 (en) | 2016-05-18 | 2017-11-23 | Merck Sharp & Dohme Corp. | Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders |
EP3538520A2 (de) | 2016-11-08 | 2019-09-18 | Cyclerion Therapeutics, Inc. | Sgc-stimulatoren |
US11083199B2 (en) | 2017-01-10 | 2021-08-10 | Bayer Aktiengesellschaft | Heterocycle derivatives as pesticides |
KR102615821B1 (ko) | 2017-04-11 | 2023-12-21 | 선샤인 레이크 파르마 컴퍼니 리미티드 | 불소-치환된 인다졸 화합물 및 이의 용도 |
RU2662308C1 (ru) * | 2017-12-25 | 2018-07-25 | Феркат Адельзянович Халиуллин | Средство для лечения и профилактики тромбоза |
EP3925953A1 (de) * | 2020-06-16 | 2021-12-22 | Adverio Pharma GmbH | Verfahren zur herstellung von methyl-{4,6-diamino-2-[5-fluor-1-(2-fluorbenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamat |
Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1029653A (en) | 1910-05-11 | 1912-06-18 | Waterbury Farrel Foundry Co | Slotting-machine. |
EP0634413A1 (de) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Herbizide |
WO2000006568A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Substituierte pyrazolderivate |
WO2000006569A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate |
WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
WO2004009590A1 (de) | 2002-07-18 | 2004-01-29 | Bayer Healthcare Ag | 4-aminosubstituierte pyrimidinderivate |
CN1613849A (zh) | 2003-11-03 | 2005-05-11 | 上海药明康德新药开发有限公司 | 2-氯-5-氟-烟酸酯及酸的制备方法 |
EP1626045A1 (de) | 2003-05-09 | 2006-02-15 | Asahi Glass Company, Limited | Verfahren zur herstellung von 3-substituiertem 2-chlor-5-fluorpyridin bzw. einem salz davon |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2009018415A1 (en) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
WO2010065275A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2011149921A1 (en) | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2012004258A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
WO2012004259A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | Annellierte 4 -aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
WO2012028647A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Bicyclische aza-heterocyclen und ihre verwendung |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0743066A3 (de) | 1995-05-16 | 1998-09-30 | Mitsui Pharmaceuticals, Inc. | Wundheilmittel |
DE19642255A1 (de) | 1996-10-14 | 1998-04-16 | Bayer Ag | Verwendung von 1-Benzyl-3-(substituierten-hetaryl) -kondensierten Pyrazol-Derivaten |
US6451805B1 (en) | 1997-11-14 | 2002-09-17 | Bayer Aktiengesellschaft | Substituted pyrazole derivatives for the treatment of cardiocirculatory diseases |
DE10021069A1 (de) | 2000-04-28 | 2001-10-31 | Bayer Ag | Substituiertes Pyrazolderivat |
AU2002221827A1 (en) | 2000-11-22 | 2002-06-03 | Bayer Aktiengesellschaft | Novel lactame-substituted pyrazolopyridine derivatives |
DE10132416A1 (de) | 2001-07-04 | 2003-01-16 | Bayer Ag | Neue Morpholin-überbrückte Pyrazolopyridinderivate |
DE102006043443A1 (de) | 2006-09-15 | 2008-03-27 | Bayer Healthcare Ag | Neue aza-bicyclische Verbindungen und ihre Verwendung |
JP2011513483A (ja) | 2008-03-10 | 2011-04-28 | バーテックス ファーマシューティカルズ インコーポレイテッド | タンパク質キナーゼの阻害剤として有用なピリミジンおよびピリジン |
CN103619845B (zh) | 2011-04-21 | 2016-08-17 | 拜耳知识产权有限责任公司 | 氟烷基取代的吡唑并吡啶及其用途 |
ES2592267T3 (es) * | 2011-05-06 | 2016-11-29 | Bayer Intellectual Property Gmbh | Imidazopiridinas e imidazopiridazinas sustituidas y su uso |
MX2014000029A (es) * | 2011-07-06 | 2014-02-17 | Bayer Ip Gmbh | Pirazolopiridinas sustituidas con heteroarilo y uso de las mismas como estimuladores de guanilato ciclasas solubles. |
-
2012
- 2012-08-30 WO PCT/EP2012/066876 patent/WO2013030288A1/de active Application Filing
- 2012-08-30 AU AU2012300844A patent/AU2012300844B2/en not_active Ceased
- 2012-08-30 EA EA201490546A patent/EA026701B1/ru not_active IP Right Cessation
- 2012-08-30 BR BR112014005110A patent/BR112014005110A2/pt active Search and Examination
- 2012-08-30 MX MX2014002075A patent/MX348470B/es active IP Right Grant
- 2012-08-30 CN CN201280053847.5A patent/CN104039784B/zh not_active Expired - Fee Related
- 2012-08-30 EP EP12766292.2A patent/EP2751106B1/de active Active
- 2012-08-30 SG SG11201400083VA patent/SG11201400083VA/en unknown
- 2012-08-30 KR KR1020147008313A patent/KR20140068112A/ko unknown
- 2012-08-30 AP AP2014007541A patent/AP2014007541A0/xx unknown
- 2012-08-30 US US13/599,975 patent/US8859569B2/en not_active Expired - Fee Related
- 2012-08-30 JP JP2014527659A patent/JP6054967B2/ja not_active Expired - Fee Related
- 2012-08-30 CA CA 2847075 patent/CA2847075A1/en not_active Abandoned
- 2012-08-30 PE PE2014000263A patent/PE20141582A1/es not_active Application Discontinuation
- 2012-08-31 TW TW101131665A patent/TWI565708B/zh not_active IP Right Cessation
- 2012-08-31 UY UY0001034306A patent/UY34306A/es not_active Application Discontinuation
- 2012-09-03 AR ARP120103249A patent/AR087769A1/es active Pending
-
2014
- 2014-02-21 CO CO14037097A patent/CO6950471A2/es active IP Right Grant
- 2014-02-26 GT GT201400033A patent/GT201400033A/es unknown
- 2014-02-27 CR CR20140096A patent/CR20140096A/es unknown
- 2014-02-28 EC ECSP14013224 patent/ECSP14013224A/es unknown
- 2014-02-28 MA MA36787A patent/MA35365B1/fr unknown
- 2014-02-28 CL CL2014000504A patent/CL2014000504A1/es unknown
- 2014-02-28 DO DO2014000043A patent/DOP2014000043A/es unknown
- 2014-03-02 IL IL231244A patent/IL231244A/en not_active IP Right Cessation
- 2014-03-03 CU CUP2014000025A patent/CU20140025A7/es unknown
- 2014-09-19 US US14/491,558 patent/US20150105374A1/en not_active Abandoned
- 2014-12-04 HK HK14112217.6A patent/HK1198698A1/xx unknown
Patent Citations (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1029653A (en) | 1910-05-11 | 1912-06-18 | Waterbury Farrel Foundry Co | Slotting-machine. |
EP0634413A1 (de) | 1993-07-13 | 1995-01-18 | Rhone Poulenc Agriculture Ltd. | Herbizide |
WO2000006568A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Substituierte pyrazolderivate |
WO2000006569A1 (de) | 1998-07-29 | 2000-02-10 | Bayer Aktiengesellschaft | Mit sechsgliedrigen heterocyclischen ringen kondensierte substituierte pyrazolderivate |
WO2003095451A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Carbamat-substituierte pyrazolopyridine |
WO2004009590A1 (de) | 2002-07-18 | 2004-01-29 | Bayer Healthcare Ag | 4-aminosubstituierte pyrimidinderivate |
EP1626045A1 (de) | 2003-05-09 | 2006-02-15 | Asahi Glass Company, Limited | Verfahren zur herstellung von 3-substituiertem 2-chlor-5-fluorpyridin bzw. einem salz davon |
CN1613849A (zh) | 2003-11-03 | 2005-05-11 | 上海药明康德新药开发有限公司 | 2-氯-5-氟-烟酸酯及酸的制备方法 |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2009018415A1 (en) | 2007-07-31 | 2009-02-05 | Vertex Pharmaceuticals Incorporated | Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof |
WO2010065275A1 (en) | 2008-11-25 | 2010-06-10 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2011115804A1 (en) | 2010-03-17 | 2011-09-22 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2011149921A1 (en) | 2010-05-27 | 2011-12-01 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
WO2012004258A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen |
WO2012004259A1 (de) | 2010-07-09 | 2012-01-12 | Bayer Pharma Aktiengesellschaft | Annellierte 4 -aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase |
WO2012028647A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Pharma Aktiengesellschaft | Bicyclische aza-heterocyclen und ihre verwendung |
Non-Patent Citations (20)
Title |
---|
"Maarten van den Buuse: Circadian Rhythms of Blood Pressure, Heart Rate, and Locomotor Activity in Spontaneously Hypertensive Rats as Measured With Radio-Telemetry", PHYSIOLOGY & BEHAVIOR, vol. 55, no. 4, 1994, pages 783 - 787 |
C.C. CHENG; R.K. ROBINS, J. ORG. CHEM., vol. 23, 1958, pages 191 |
E. M. BECKER ET AL., BMC PHARMACOLOGY, vol. 1, 2001, pages 13 |
F. WUNDER ET AL., ANAL. BIOCHEM., vol. 339, 2005, pages 104 - 112 |
FOELDI ET AL., CHEMISCHE BERICHTE, vol. 75, 1942, pages 760 |
HUGHES, D. L., ORG. PREP. PROCEED. INT., vol. 28, 1996, pages 127 |
HUGHES, D. L.: "Organic Reactions", vol. 42, 1992, JOHN WILEY & SONS, LTD, article "The Mitsunobu Reaction", pages: 335 |
J. ORG. CHEM., vol. 23, 1958, pages 191 |
JUSTUS LIEBIGS ANNALEN DER CHEMIE, 1970, pages 99 - 107 |
KLAUS WITTE; KAI HU; JOHANNA SWIATEK; CLAUDIA MÜSSIG; GEORG ERTL; BJÖRN LEMMER: "Experimental heart failure in rats: effects on cardiovascular circadian rhythms and on myocardial ?-adrenergic signaling", CARDIOVASC RES, vol. 47, no. 2, 2000, pages 203 - 405 |
KOZO OKAMOTO: "Spontaneous hypertension in rats", INT REV EXP PATHOL, vol. 7, 1969, pages 227 - 270 |
MÜLSCH ET AL., BRIT. J. PHARMACOL., vol. 120, 1997, pages 681 |
OUDOUT ET AL., EUR. UROL., vol. 60, 2011, pages 1020 - 1026 |
SHARKOVSKA Y; KALK P; LAWRENZ B; GODES M; HOFFMANN LS; WELLKISCH K; GESCHKA S; RELLE K; HOCHER B; STASCH JP: "NOindependent stimulation of soluble guanylate cyclase reduces target organ damage in lowand high-renin models of hypertension", J. HYPERTENSION, vol. 28, 2010, pages 1666 - 1675 |
STASCH J.-P. ET AL., CHEMMEDCHEM, vol. 4, 2009, pages 853 - 865 |
STASCH J.-P. ET AL., CIRCULATION, 2011 |
STASCH J.-P. ET AL., CIRCULATION, vol. 123, 2011, pages 2263 - 2273 |
STASCH J.-P. ET AL., NAT. REV. DRUG DISC., vol. 5, 2006, pages 755 - 768 |
WINN M., J. MED. CHEM., vol. 36, 1993, pages 2676 - 7688 |
WU ET AL., BLOOD, vol. 84, 1994, pages 4226 |
Cited By (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9636399B2 (en) | 2007-11-21 | 2017-05-02 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
US10577428B2 (en) | 2007-11-21 | 2020-03-03 | Oregon Health & Science University | Anti-factor XI monoclonal antibodies and methods of use thereof |
US9637550B2 (en) | 2008-12-18 | 2017-05-02 | Oregon Health & Science University | Anti-fXI antibodies and methods of use |
US10633357B2 (en) | 2011-11-25 | 2020-04-28 | Adverio Pharma Gmbh | Intermediates and process for preparing intermediates in the production of substituted pyrazolopyridines |
US10364229B2 (en) | 2011-11-25 | 2019-07-30 | Adverio Pharma Gmbh | Crystalline substituted 5-fluoro-1H-pyrazolopyridines and process for preparing |
US10633356B2 (en) | 2011-11-25 | 2020-04-28 | Adverio Pharma Gmbh | Hydrates of substituted 5-fluoro-1H-pyrazolopyridines |
US8957210B2 (en) * | 2011-12-12 | 2015-02-17 | Pharmablock (Nanjing) R&D Co., Ltd. | Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-formamidine hydrochloride |
US20140309425A1 (en) * | 2011-12-12 | 2014-10-16 | Pharmablock (Nanjing) R&D Co., Ltd. | Method for synthesizing 1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridine-3-formamidine hydrochloride |
WO2013131923A1 (de) * | 2012-03-06 | 2013-09-12 | Bayer Intellectual Property Gmbh | Substituierte azabicyclen und ihre verwendung |
US9498480B2 (en) | 2012-03-06 | 2016-11-22 | Bayer Intellectual Property Gmbh | Substituted azabicycles and use thereof |
JP2015509515A (ja) * | 2012-03-06 | 2015-03-30 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | 置換アザ二環およびその使用 |
US10040866B2 (en) | 2012-05-10 | 2018-08-07 | Bayer Pharma Aktiengesellschaft | Nucleic acids and host cells expressing antibodies capable of binding to the coagulation factor XIa and uses thereof |
US9783614B2 (en) | 2012-05-10 | 2017-10-10 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor Xia and uses thereof |
US11046783B2 (en) | 2012-05-10 | 2021-06-29 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor XIa and uses thereof |
US10221247B2 (en) | 2012-05-10 | 2019-03-05 | Bayer Pharma Aktiengesellschaft | Antibodies capable of binding to the coagulation factor XIa and uses thereof |
WO2014084312A1 (ja) | 2012-11-30 | 2014-06-05 | アステラス製薬株式会社 | イミダゾピリジン化合物 |
CN105026405A (zh) * | 2013-03-01 | 2015-11-04 | 拜耳制药股份公司 | 苄基-取代的吡唑并吡啶及其用途 |
EA027689B1 (ru) * | 2013-03-01 | 2017-08-31 | Байер Фарма Акциенгезельшафт | Трифторметилзамещенные аннелированные пиримидины и их применение |
WO2014131760A1 (de) | 2013-03-01 | 2014-09-04 | Bayer Pharma Aktiengesellschaft | Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung |
WO2014131741A1 (de) | 2013-03-01 | 2014-09-04 | Bayer Pharma Aktiengesellschaft | Benzyl-substituierte pyrazolopyridine und ihre verwendung |
US9776997B2 (en) | 2013-06-04 | 2017-10-03 | Bayer Pharma Aktiengesellschaft | 3-aryl-substituted imidazo[1,2-A]pyridines and their use |
JP2016523944A (ja) * | 2013-07-10 | 2016-08-12 | バイエル・ファルマ・アクティエンゲゼルシャフト | ベンジル−1H−ピラゾロ[3,4−b]ピリジンおよびその使用 |
WO2015088885A1 (en) | 2013-12-11 | 2015-06-18 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
EP3079701A4 (de) * | 2013-12-11 | 2017-07-19 | Merck Sharp & Dohme Corp. | Lösliche guanylat-cyclase-aktivatoren |
EP3079700A4 (de) * | 2013-12-11 | 2017-07-19 | Merck Sharp & Dohme Corp. | Lösliche guanylat-cyclase-aktivatoren |
WO2015089182A1 (en) | 2013-12-11 | 2015-06-18 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
WO2015106268A1 (en) | 2014-01-13 | 2015-07-16 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
CN106459090A (zh) * | 2014-02-19 | 2017-02-22 | 拜耳制药股份公司 | 3‑(嘧啶‑2‑基)咪唑并[1,2‑a]吡啶 |
WO2015124544A1 (de) * | 2014-02-19 | 2015-08-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidin-2-yl)imidazo[1,2-a]pyridine |
US9688699B2 (en) | 2014-02-19 | 2017-06-27 | Bayer Pharma Aktiengesellschaft | 3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines |
WO2016030362A1 (de) | 2014-08-29 | 2016-03-03 | Bayer Pharma Aktiengesellschaft | Substituierte annellierte pyrimidine und ihre verwendung |
US20170240566A1 (en) * | 2014-08-29 | 2017-08-24 | Bayer Pharma Aktiengesellschaft | Amino-substituted annulated pyrimidines and use thereof |
CN107074883A (zh) * | 2014-08-29 | 2017-08-18 | 拜耳医药股份有限公司 | 氨基取代的环状嘧啶及其用途 |
WO2016030354A1 (de) | 2014-08-29 | 2016-03-03 | Bayer Pharma Aktiengesellschaft | Amino-substituierte annellierte pyrimidine und ihre verwendung |
WO2016044446A2 (en) | 2014-09-17 | 2016-03-24 | Ironwood Pharmaceuticals, Inc. | Sgc stimulators |
US10570135B2 (en) | 2014-11-06 | 2020-02-25 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-A]pyrimidines and their use in the treatment of medical disorders |
US11400095B2 (en) | 2014-11-06 | 2022-08-02 | Bial—R&D Investments, S.A. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US10751341B2 (en) | 2014-11-06 | 2020-08-25 | Lysosomal Therapeutics Inc. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US11091492B2 (en) | 2014-11-06 | 2021-08-17 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US9732089B2 (en) | 2014-11-06 | 2017-08-15 | Lysosomal Therapeutics Inc. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US10786508B2 (en) | 2014-11-06 | 2020-09-29 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders |
US11932645B2 (en) | 2014-11-06 | 2024-03-19 | Bial—R & D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
WO2016073889A1 (en) * | 2014-11-06 | 2016-05-12 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,5-a]pyrimidines and their use in the treatment of medical disorders |
US11351173B2 (en) | 2014-11-06 | 2022-06-07 | Bial—R&D Investments, S.A. | Substituted pyrrolo[1,2-a]pyrimidines and their use in the treatment of medical disorders |
US10292970B2 (en) | 2014-12-02 | 2019-05-21 | Bayer Pharma Aktiengesellschaft | Heteroaryl-substituted imidazo[1,2-A]pyridines and their use |
WO2016110821A1 (en) | 2015-01-08 | 2016-07-14 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
WO2016177660A1 (en) | 2015-05-06 | 2016-11-10 | Bayer Pharma Aktiengesellschaft | The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc) |
WO2017013010A1 (de) | 2015-07-23 | 2017-01-26 | Bayer Pharma Aktiengesellschaft | Stimulatoren und/oder aktivatoren der löslichen guanylatzyklase (sgc) in kombination mit einem inhibitor der neutralen endopeptidase (nep inhibitor) und/oder einem angiotensin aii-antagonisten und ihre verwendung |
US11166932B2 (en) | 2015-07-23 | 2021-11-09 | Bayer Pharma Aktiengesellschaft | Stimulators and/or activators of soluble guanylate cyclase (sGC) in combination with an inhibitor of neutral endopeptidase (NEP inhibitor) and/or an angiotensin AII antagonist and the use thereof |
WO2017106175A2 (en) | 2015-12-14 | 2017-06-22 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION |
KR102191312B1 (ko) | 2015-12-22 | 2020-12-15 | 머크 샤프 앤드 돔 코포레이션 | 심혈관 질환을 치료하기 위한 cGMP 조정제로서의 4-아미노-2-(1H-피라졸로[3,4-B]피리딘-3-일)-6-옥소-6,7-디히드로-5H-피롤로[2,3-D]피리딘 유도체 및 각각의 (1H-인다졸-3-일) 유도체 |
KR20180095904A (ko) * | 2015-12-22 | 2018-08-28 | 머크 샤프 앤드 돔 코포레이션 | 심혈관 질환을 치료하기 위한 cGMP 조정제로서의 4-아미노-2-(1H-피라졸로[3,4-B]피리딘-3-일)-6-옥소-6,7-디히드로-5H-피롤로[2,3-D]피리딘 유도체 및 각각의 (1H-인다졸-3-일) 유도체 |
US10787454B2 (en) | 2016-04-06 | 2020-09-29 | BIAL—BioTech Investments, Inc. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US9840510B1 (en) | 2016-04-06 | 2017-12-12 | Lysosomal Therapeutics Inc. | Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US10934298B2 (en) | 2016-04-06 | 2021-03-02 | BIAL—BioTech Investments, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US11453675B2 (en) | 2016-04-06 | 2022-09-27 | Bial—R&D Investments, S.A. | Imidazo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11124516B2 (en) | 2016-04-06 | 2021-09-21 | BIAL-BioTech Investments, Inc. | Pyrrolo[1,2-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US9920061B2 (en) | 2016-04-06 | 2018-03-20 | Lysosomal Therapeutics Inc. | Imidazo[1,5-A]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders |
US11192892B2 (en) | 2016-04-06 | 2021-12-07 | Bial—R&D Investments, S.A. | Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders |
US11345698B2 (en) | 2016-05-05 | 2022-05-31 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-a]pyrazines, related compounds, and their use in the treatment of medical disorders |
US11878979B2 (en) | 2016-05-05 | 2024-01-23 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US9868742B2 (en) | 2016-05-05 | 2018-01-16 | Lysosomal Therapeutics Inc. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders |
US11168087B2 (en) | 2016-05-05 | 2021-11-09 | Bial—R&D Investments, S.A. | Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders |
US11684621B2 (en) | 2016-10-11 | 2023-06-27 | Bayer Pharma Aktiengesellschaft | Combination containing sGC stimulators and mineralocorticoid receptor antagonists |
US11331308B2 (en) | 2016-10-11 | 2022-05-17 | Bayer Pharma Aktiengesellschaft | Combination containing sGC activators and mineralocorticoid receptor antagonists |
WO2018069126A1 (de) | 2016-10-11 | 2018-04-19 | Bayer Pharma Aktiengesellschaft | Kombination enthaltend sgc stimulatoren und mineralocorticoid-rezeptor-antagonisten |
US10918639B2 (en) | 2016-10-11 | 2021-02-16 | Bayer Pharma Aktiengesellschaft | Combination containing SGC stimulators and mineralocorticoid receptor antagonists |
WO2018111795A2 (en) | 2016-12-13 | 2018-06-21 | Ironwood Pharmaceuticals, Inc. | Use of sgc stimulators for the treatment of esophageal motility disorders |
WO2019219672A1 (en) | 2018-05-15 | 2019-11-21 | Bayer Aktiengesellschaft | 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization |
WO2020014504A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS |
WO2020165010A1 (en) | 2019-02-13 | 2020-08-20 | Bayer Aktiengesellschaft | Process for the preparation of porous microparticles |
US11767337B2 (en) | 2020-02-18 | 2023-09-26 | Gilead Sciences, Inc. | Antiviral compounds |
US11697666B2 (en) | 2021-04-16 | 2023-07-11 | Gilead Sciences, Inc. | Methods of preparing carbanucleosides using amides |
WO2024038398A1 (en) * | 2022-08-18 | 2024-02-22 | Torrent Pharmaceuticals Limited | Novel salt of substituted 5-fluoro-1h-pyrazolopyridines and its uses |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2751106B1 (de) | Substituierte annellierte pyrimidine und ihre verwendung | |
EP2802587B1 (de) | Substituierte, annellierte imidazole und pyrazole und ihre verwendung | |
EP2822951B1 (de) | Substituierte azabicyclen und ihre verwendung | |
EP2611802B1 (de) | Bicyclische aza-heterocyclen und ihre verwendung | |
WO2013104703A1 (de) | Substituierte annellierte pyrimidine und triazine und ihre verwendung | |
WO2012004258A9 (de) | Annellierte pyrimidine und triazine und ihre verwendung zur behandlung bzw. prophylaxe von herz-kreislauf-erkrankungen | |
EP2729476A1 (de) | Heteroaryl-substituierte pyrazolopyridine und ihre verwendung als stimulatoren der löslichen guanylatcyclase | |
WO2012004259A1 (de) | Annellierte 4 -aminopyrimidine und ihre verwendung als stimulatoren der löslichen guanylatcyclase | |
WO2014131760A1 (de) | Trifluormethyl-substituierte annellierte pyrimidine und ihre verwendung | |
EP2705037A1 (de) | Substituierte imidazopyridine und imidazopyridazine und ihre verwendung | |
WO2017121700A1 (de) | 1,3-disubstituierte 1h-pyrazolo[3,4-b]pyridin- derivate und ihre verwendung als stimulatoren der löslichen guanylatcyclase | |
EP3186255A1 (de) | Amino-substituierte annellierte pyrimidine und ihre verwendung | |
EP3186251A1 (de) | Substituierte annellierte pyrimidine und ihre verwendung | |
WO2017121692A1 (de) | Substituierte sulfamide und ihre verwendung | |
DE102012200351A1 (de) | Substituierte annellierte Pyrimidine und ihre Verwendung | |
NZ621396B2 (en) | Substituted annellated pyrimidine and the use thereof | |
DE102012200354A1 (de) | Heteroaryl-substituierte Pyrazolopyridine und ihre Verwendung | |
DE102011003315A1 (de) | Annellierte Pyrimindine und Triazine und ihre Verwendung | |
DE102010031149A1 (de) | Annellierte Pyrimidine und Triazine und ihre Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12766292 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14037097 Country of ref document: CO Ref document number: MX/A/2014/002075 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 000263-2014 Country of ref document: PE |
|
ENP | Entry into the national phase |
Ref document number: 2847075 Country of ref document: CA |
|
REEP | Request for entry into the european phase |
Ref document number: 2012766292 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012766292 Country of ref document: EP Ref document number: CR2014-000096 Country of ref document: CR |
|
ENP | Entry into the national phase |
Ref document number: 2014527659 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014000504 Country of ref document: CL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 231244 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012300844 Country of ref document: AU Date of ref document: 20120830 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 20147008313 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201401862 Country of ref document: ID |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201403255 Country of ref document: UA Ref document number: 201490546 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005110 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005110 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140305 |